p53 gene mutations occur in combination with 17p alleli colorectal tumorigenesis

Cancer Research

50, 7717-22

Citation Report

#	Article	IF	Citations
1	Timing and role of p53 gene mutation in the recurrence of glioma. Biochemical and Biophysical Research Communications, 1991, 180, 1145-1150.	1.0	40
2	Identification of FAP locus genes from chromosome 5q21. Science, 1991, 253, 661-665.	6.0	2,257
3	Tumor suppressor genes. Science, 1991, 254, 1138-1146.	6.0	1,553
4	Mutations of the p53 gene, including an intronic point mutation, in colorectal tumors. Biochemical and Biophysical Research Communications, 1991, 177, 901-906.	1.0	19
5	p53 mutations in human cancers. Science, 1991, 253, 49-53.	6.0	7,591
6	Identification of p53 as a sequence-specific DNA-binding protein. Science, 1991, 252, 1708-1711.	6.0	1,085
7	Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. British Journal of Cancer, 1991, 64, 1076-1082.	2.9	369
8	Reduction to homozygosity involving p53 in esophageal cancers demonstrated by the polymerase chain reaction.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 4976-4980.	3.3	136
9	Telling changes of base. Nature, 1991, 350, 377-378.	13.7	55
10	Genetic alterations within the retinoblastoma locus in colorectal carcinomas. Relation to DNA ploidy pattern studied by flow cytometric analysis. British Journal of Cancer, 1991, 64, 475-480.	2.9	60
11	Transforming activity of mutant human p53 alleles. Journal of Cellular Physiology, 1991, 148, 391-395.	2.0	21
12	p53 Protein alterations in human testicular cancer including pre-invasive intratubular germ-cell neoplasia. International Journal of Cancer, 1991, 49, 196-202.	2.3	140
13	Adult T-cell leukemia: Structures and expression of thep53 gene. International Journal of Cancer, 1991, 49, 880-885.	2.3	41
14	Human cutaneous malignant melanoma as a model for cancer. Cancer and Metastasis Reviews, 1991, 10, 83-88.	2.7	30
16	Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science, 1991, 253, 665-669.	6.0	1,780
17	Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science, 1991, 251, 1366-1370.	6.0	757
18	Mutational Spectra and Immunohistochemical Analyses of p53 in Human Cancers. Chest, 1992, 101, 19S-20S.	0.4	31
19	Prevalence and Spectrum of Germline Mutations of the p53 Gene among Patients with Sarcoma. New England Journal of Medicine, 1992, 326, 1301-1308.	13.9	295

#	Article	IF	Citations
20	Detection of point mutations in human DNA by analysis of RNA conformation polymorphism(s). Nucleic Acids Research, 1992, 20, 573-579.	6.5	57
21	Conformational Effects Of Selected Cancer-Related Amino Acid Substitutions In The p53 Protein. Journal of Biomolecular Structure and Dynamics, 1992, 10, 253-264.	2.0	9
22	Distinct hypermethylation patterns occur at altered chromosome loci in human lung and colon cancer.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 1929-1933.	3.3	144
23	Germ-line mutations of the APC gene in 53 familial adenomatous polyposis patients.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 4452-4456.	3.3	537
24	Molecular Biology in the Diagnosis and Prognosis of Solid and Lymphoid Tumors. Cancer Investigation, 1992, 10, 399-416.	0.6	6
25	Germ-line and somatic p53 gene mutations in multifocal osteogenic sarcoma.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 4207-4209.	3.3	63
26	Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. Gastroenterology, 1992, 102, 1220-1228.	0.6	162
27	Survival and acquired genetic alterations in colorectal cancer. Gastroenterology, 1992, 102, 1136-1141.	0.6	182
28	p53 Gene mutations in gastric and esophageal cancers. Gastroenterology, 1992, 103, 892-896.	0.6	69
29	The relationship of DNA aneuploidy to molecular genetic alterations in colorectal carcinoma. Gastroenterology, 1992, 102, 1612-1619.	0.6	112
30	Neoplastic progression in ulcerative colitis: Histology, DNA content, and loss of a p53 allele. Gastroenterology, 1992, 103, 1602-1610.	0.6	277
31	Increased expression and mutation of p53 in choroidal melanoma. British Journal of Cancer, 1992, 66, 900-904.	2.9	39
32	Molecular Genetic Characterization of Cns Tumor Oncogenesis. Advances in Cancer Research, 1992, 58, 121-142.	1.9	18
33	Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 7262-7266.	3.3	533
34	p53 Expression in Human Breast Cancer. Advances in Cancer Research, 1992, 59, 69-88.	1.9	38
35	Similarity of spontaneous germinal and in vitro somatic cell mutation rates in humans: implications for carcinogenesis and for the role of exogenous factors in "spontaneous" germinal mutagenesis.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 7036-7040.	3.3	34
36	Missense mutations and a deletion of the p53 gene in human gastric cancer. Biochemical and Biophysical Research Communications, 1992, 182, 215-223.	1.0	50
37	Papillomaviruses, p53, and cervical cancer. Lancet, The, 1992, 339, 1350-1351.	6.3	49

#	Article	IF	Citations
38	The p53 gene in human cancer. European Journal of Cancer, 1992, 28, 293-295.	1.3	16
39	Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell, 1992, 70, 937-948.	13.5	1,116
40	Oncogenes and tumour-suppressor genes in squamous cell carcinoma of the head and neck. European Journal of Cancer Part B, Oral Oncology, 1992, 28, 67-76.	0.9	141
41	Mutant conformation of p53. Journal of Molecular Biology, 1992, 225, 577-583.	2.0	224
42	Genes in the diagnosis of malignant disease. Clinica Chimica Acta, 1992, 209, S15-S26.	0.5	1
43	Tumor-suppressor genes: cardinal factors in inherited predisposition to human cancers.. Environmental Health Perspectives, 1992, 98, 25-37.	2.8	15
44	Oncogenes in Ovarian Cancer. Hematology/Oncology Clinics of North America, 1992, 6, 813-827.	0.9	20
45	Absence of p53 germ-line mutations in bilateral breast cancer patients. Human Genetics, 1992, 89, 250-2.	1.8	28
46	Aberrant expression of the tumour suppressor gene p53 is very frequent in Wilms' tumours. Journal of Pathology, 1992, 168, 237-242.	2.1	29
47	APC mutations occur early during colorectal tumorigenesis. Nature, 1992, 359, 235-237.	13.7	1,731
48	Infrequent Mutation of p53 Gene in Human Renal Cell Carcinoma Detected by Polymerase Chain Reaction Single-strand Conformation Polymorphism Analysis. Japanese Journal of Cancer Research, 1992, 83, 233-235.	1.7	51
49	p53 Gene Mutations in Esophageal Cancer Detected by Polymerase Chain Reaction Singleâ€strand Conformation Polymorphism Analysis. Japanese Journal of Cancer Research, 1992, 83, 559-562.	1.7	33
50	High Incidence of p53 Gene Mutation in Human Ovarian Cancer and Its Association with Nuclear Accumulation of p53 Protein and Tumor DNA Aneuploidy. Japanese Journal of Cancer Research, 1992, 83, 978-984.	1.7	100
51	Insertion/Deletion Polymorphism and Other Restriction Fragment Length Polymorphisms in theMCCGene. Japanese Journal of Cancer Research, 1992, 83, 10-14.	1.7	4
52	Clinicopathological Significance of Nuclear Accumulation of Tumor Suppressor Gene p53 Product in Primary Lung Cancer. Japanese Journal of Cancer Research, 1992, 83, 101-106.	1.7	59
53	Inactivation of the p53 Gene Is not Required for Tumorigenesis of Medullary Thyroid Carcinoma or Pheochromocytoma. Japanese Journal of Cancer Research, 1992, 83, 1113-1116.	1.7	32
54	Frequent Occurrence of p53 Gene Mutations in Uterine Cancers at Advanced Clinical Stage and with Aggressive Histological Phenotypes. Japanese Journal of Cancer Research, 1992, 83, 1184-1191.	1.7	44
55	Aberrant expression of p53 tumour-suppressor protein in non-melanoma skin cancer. British Journal of Dermatology, 1992, 127, 463-469.	1.4	97

#	Article	IF	Citations
56	Recombinant DNA technology and its diagnostic applications. Histopathology, 1992, 21, 303-313.	1.6	9
57	Expression of mutant p53 gene in squamous carcinoma arising in patients with recessive dystrophic epidermolysis bullosa. Histopathology, 1992, 20, 237-241.	1.6	36
58	P53 mutations in gastric carcinomas. British Journal of Cancer, 1992, 65, 708-710.	2.9	55
59	Increased p53 protein content of colorectal tumours correlates with poor survival. British Journal of Cancer, 1992, 66, 758-764.	2.9	141
60	Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma. British Journal of Cancer, 1992, 65, 40-44.	2.9	95
61	The biology of colorectal carcinoma. Current Problems in Cancer, 1992, 16, 265-328.	1.0	10
62	New paradigms of oncogenesis and their implications for surgery in the twenty-first century. Diseases of the Colon and Rectum, 1992, 35, 627-634.	0.7	2
63	P53 gene mutations in acute myelogenous leukaemia. British Journal of Haematology, 1992, 81, 489-494.	1.2	61
64	Methylation, mutation and cancer. BioEssays, 1992, 14, 33-36.	1.2	205
65	What the papers say: p53 Loss of Function: Implications for the Processes of Immortalization and Tumorigenesis. BioEssays, 1992, 14, 557-560.	1.2	25
66	Basic science reviews: Tumor suppressor genes. Head and Neck, 1992, 14, 407-414.	0.9	4
67	Overexpression of p53: A rare event in a large series of white patients with hepatocellular carcinoma. Hepatology, 1992, 16, 1171-1175.	3.6	53
68	The adenoma-adenocarcinoma sequence in the large bowel: Variations on a theme. Journal of Cellular Biochemistry, 1992, 50, 41-46.	1.2	65
69	TP53 tumor suppressor gene: A model for investigating human mutagenesis. Genes Chromosomes and Cancer, 1992, 4, 1-15.	1.5	508
70	Screening for germ-line mutations in familial adenomatous polyposis patients: 61 new patients and a summary of 150 unrelated patients. Human Mutation, 1992, 1, 467-473.	1.1	113
71	Murine p53 intron sequences 5â€“8 and their use in polymerase chain reaction/direct sequencing analysis of p53 mutations in CDâ€1 mouse liver and lung tumors. Molecular Carcinogenesis, 1992, 5, 9-15.	1.3	65
72	p53 gene mutations in human endometrial carcinoma. Molecular Carcinogenesis, 1992, 5, 250-253.	1.3	76
73	Stepwise transformation of primary thyroid epithelial cells by a mutant Ha-ras oncogene: An in vitro model of tumor progression. Molecular Carcinogenesis, 1992, 6, 129-139.	1.3	39

#	Article	IF	Citations
74	p53 mutations are absent from carcinogen-induced mouse liver tumors but occur in cell lines established from these tumors. Molecular Carcinogenesis, 1992, 6, 148-158.	1.3	74
75	Molecular genetic alterations as potential prognostic indicators in colorectal carcinoma. Cancer, 1992, 69, 1589-1591.	2.0	25
76	Molecular markers for the diagnosis and prognosis of lung cancer. Cancer, 1992, 69, 1592-1599.	2.0	48
77	Molecular genetics of colorectal carcinoma. Cancer, 1992, 70, 1216-1221.	2.0	86
78	Colon cancer genetics. Cancer, 1992, 70, 1300-1312.	2.0	51
79	Chemotherapy for metastatic colorectal cancer. Cancer, 1992, 70, 1414-1424.	2.0	50
80	Genetic alterations in the adenomaâ€“carcinoma sequence. Cancer, 1992, 70, 1727-1731.	2.0	307
81	The future of prognostic factors in outcome prediction for patients with cancer. Cancer, 1992, 70, 2367-2377.	2.0	156
82	Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer, 1992, 70, 2778-2784.	2.0	142
83	Recessive oncogenes. Cancer, 1993, 71, 1179-1186.	2.0	27
84	Mutations of p53 and human papillomavirus infection in cervical carcinoma. Cancer, 1993, 72, 1272-1280.	2.0	83
85	Identification of dna adducts at specific locations by sequencing techniques. International Journal of Biochemistry & Cell Biology, 1993, 25, 1669-1672.	0.8	3
86	Detection of K-ras mutation in sputum by mutant-allele-specific amplification (MASA). Human Mutation, 1993, 2, 112-117.	1.1	143
87	Concordant p53 andDCC alterations and allelic losses on chromosomes 13q and 14q associated with liver metastases of colorectal carcinoma. International Journal of Cancer, 1993, 53, 382-387.	2.3	135
88	p53 Mutation in gastric cancer: A genetic model for carcinogenesis is common to gastric and colorectal cancer. International Journal of Cancer, 1993, 54, 759-764.	2.3	193
89	Sodium butyrate induces apoptosis in human colonic tumour cell lines in a p53-independent pathway: Implications for the possible role of dietary fibre in the prevention of large-bowel cancer. International Journal of Cancer, 1993, 55, 498-505.	2.3	510
90	Direct growth stimulation of normal human epithelial cells by mutantp53. Molecular Carcinogenesis, 1993, 7, 83-88.	1.3	29
91	Heritable colorectal cancer and cancer genes: Systemic expressions. Molecular Carcinogenesis, 1993, 8, 3-6.	1.3	16

#	Article	IF	Citations
92	p53 Immunoreactivity in inflammatory and neoplastic diseases of the uterine cervix. Journal of Pathology, 1993, 169, 425-430.	2.1	58
93	p53 oncogene mutations in three human prostate cancer cell lines. Prostate, 1993, 23, 123-134.	1.2	276
94	p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. British Journal of Cancer, 1993, 68, 1134-1139.	2.9	136
95	p53 protein in aggressive and non-aggressive basal cell carcinoma. Journal of Cutaneous Pathology, 1993, 20, 429-434.	0.7	38
96	Mutations of the p53 gene in carcinomas of the urinary system. Pathology International, 1993, 43, 745-750.	0.6	6
97	Genetics, molecular biology and colorectal cancer. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1993, 290, 3-12.	0.4	23
98	The tumore suppressor p53. Biochimica Et Biophysica Acta: Reviews on Cancer, 1993, 1155, 181-205.	3.3	176
99	Gene amplification and tumor progression. Biochimica Et Biophysica Acta: Reviews on Cancer, 1993, 1155, 25-41.	3.3	80
100	Ki-ras codon 12 mutation in human colorectal carcinomas. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 1993, 5, 235-239.	0.7	0
101	Immunohistochemical detection of mutant P53 protein and human papillomavirus-related E6 protein in anal cancers. Diseases of the Colon and Rectum, 1993, 36, 1026-1029.	0.7	18
102	p53 gene mutations in gastric adenomas. Vigiliae Christianae, 1993, 63, 191-195.	0.1	55
103	The role of hepatitis B virus in development of primary hepatocellular carcinoma: Part II. Journal of Gastroenterology and Hepatology (Australia), 1993, 8, 95-106.	1.4	15
104	The functions of the p53 gene and gene product. Journal of Gastroenterology and Hepatology (Australia), 1993, 8, S5-S11.	1.4	0
105	Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumours. European Journal of Cancer, 1993, 29, 881-886.	1.3	36
106	p53 Mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Letters, 1993, 69, 151-160.	3.2	177
107	Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias. American Journal of Obstetrics and Gynecology, 1993, 169, 690-694.	0.7	56
108	Familial and genetic aspects of colorectal carcinogenesis. European Journal of Cancer, 1993, 29, 2163-2167.	1.3	10
109	Localization of p53 protein and human papillomavirus in anogenital squamous lesions: Immunohistochemical and in situ hybridization studies in benign, dysplastic, and malignant epithelia. Human Pathology, 1993, 24, 1238-1242.	1.1	26

#	Article	IF	Citations
110	Mutations of the p53 Gene in B-cell Lymphoma. Leukemia and Lymphoma, 1993, 11, 21-25.	0.6	20
111	p53 expression and K-ras mutation in colorectal adenomas.. Gut, 1993, 34, 621-624.	6.1	41
112	Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 4216-4220.	3.3	691
113	The Role of the Adenomatous Polyposis Coli (Apc) Gene in Human Cancers. Advances in Cancer Research, 1993, 62, 65-87.	1.9	63
114	The TP53 tumour suppressor gene in colorectal carcinomas. I. Genetic alterations on chromosome 17. British Journal of Cancer, 1993, 67, 88-92.	2.9	25
115	Over-expression of the c-myc proto-oncogene in colorectal carcinoma. British Journal of Cancer, 1993, 68, 407-413.	2.9	80
116	Biliary glycoprotein, a potential human cell adhesion molecule, is down-regulated in colorectal carcinomas.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 10744-10748.	3.3	214
117	p53 Point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology, 1993, 104, 1633-1639.	0.6	220
118	Detection of 12 germ-line mutations in the adenomatous polyposis coli gene by polymerase chain reaction. Gastroenterology, 1993, 104, 989-993.	0.6	24
119	REVIEW Colon Cancer : An Approach from Molecular Epidemiology. Journal of Epidemiology, 1993, 3, 47-61.	1.1	39
120	p53: A target for new anticancer drugs or a target for old drugs?. Annals of Oncology, 1993, 4, 623-629.	0.6	4
121	The Polyp-Cancer Sequence: Do All Colorectal Cancers Arise from Benign Adenomas?. Gastrointestinal Endoscopy Clinics of North America, 1993, 3, 611-622.	0.6	6
122	Genetic Events Responsible for Colorectal Tumorigenesis: Achievements and Challenges. Tumori, 1993, 79, 235-243.	0.6	8
123	Molecular Biology of Neoplastic Transformation of the Large Bowel: Identification of Two Etiologic Pathways. Surgical Oncology Clinics of North America, 1994, 3, 449-477.	0.6	8
124	Markers of Risk for Human Malignancies. Hematology/Oncology Clinics of North America, 1994, 8, 471-483.	0.9	2
125	Genetic Aberrations in Human Brain Tumors. Neurosurgery, 1994, 34, 708-722.	0.6	52
126	Geographic variation of p53 mutational profile in nonmalignant human liver. Science, 1994, 264, 1317-1319.	6.0	279
127	Comparative clinicopathological and immunohistochemical study of ras and p53 in flat and polypoid type colorectal tumours.. Gut, 1994, 35, 1258-1261.	6.1	61

#	Article	IF	Citations
128	Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence.. Gut, 1994, 35, 764-768.	6.1	50
129	Molecular Biology and the Early Detection of Carcinoma of the Bladder -- The Case of Hubert H. Humphrey. New England Journal of Medicine, 1994, 330, 1276-1278.	13.9	70
130	Rapid detection of loss of heterozygosity of chromosome 17p by polymerase chain reaction-based variable number of tandem repeat analysis and detection of single-strand conformation polymorphism of intragenic p53 polymorphisms. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1994, 424, 337-42.	1.4	11
131	The relationship between aneuploidy and p53 overexpression during genesis of colorectal adenocarcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1994, 424, 343-7.	1.4	36
132	Detection of c-Ki-ras gene mutation in paraffin sections of adenocarcinoma and atypical bronchioloalveolar cell hyperplasia of human lung. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1994, 424, 129-34.	1.4	64
133	p53 mutations in gastric and colorectal cancers in Texas Hispanics versus Anglos. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1994, 424, 187-93.	1.4	19
134	Accumulation of the p53 protein occurs more frequently in metastatic than in localized prostatic adenocarcinomas. Prostate, 1994, 25, 243-248.	1.2	53
135	An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. Journal of Pathology, 1994, 172, 5-12.	2.1	500
136	Molecular genetic studies of early breast cancer evolution. Breast Cancer Research and Treatment, 1994, 32, 5-12.	1.1	111
137	Lack of association of human polyomaviruses with human brain tumors. Journal of Neuro-Oncology, 1994, 20, 55-58.	1.4	56
138	DNA recombination induced by aflatoxin B1 activated by cytochrome P450 1A enzymes. Molecular Carcinogenesis, 1994, 11, 227-235.	1.3	33
139	Low rate of ret proto-oncogene activation (PTC/retTPC) in papillary thyroid carcinomas from saudi arabia. Cancer, 1994, 73, 176-180.	2.0	107
140	High frequency of allelic deletion on chromosome 17p in advanced colorectal cancer. Cancer, 1994, 73, 28-35.	2.0	42
141	Allelotype and loss of heterozygosity of p53 in primary and recurrent hepatocellular carcinomas. A study of 150 patients. Cancer, 1994, 73, 42-47.	2.0	52
142	Molecular genetics for clinical management of colorectal carcinoma. 17p, 18q, and 22q loss of heterozygosity and decreased DCC expression are correlated with the metastatic potential. Cancer, 1994, 73, 1324-1331.	2.0	101
143	Observations on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53. Cancer, 1994, 73, 1686-1692.	2.0	44
144	p53 expression in pseudoepitheliomatous hyperplasia, keratoacanthoma, and squamous cell carcinoma of skin. Cancer, 1994, 73, 2317-2323.	2.0	60
145	Prognostic significance of the loss of heterozygosity of nm23-h1 and p53 genes in human colorectal carcinomas. Cancer, 1994, 73, 2913-2921.	2.0	65

#	Article	IF	Citations
146	Overexpression and point mutations of p53 tumor suppressor gene in hepatocellular carcinomas in Hong Kong Chinese people. Cancer, 1994, 74, 30-37.	2.0	49
147	The emerging picture of p53. International Journal of Biochemistry & Cell Biology, 1994, 26, 145-154.	0.8	38
148	The spectrum of TP53 mutations in bladder carcinoma. Genes Chromosomes and Cancer, 1994, 9, 108-118.	1.5	49
149	Clonal karyotypic abnormalities in colorectal adenomas: Clues to the early genetic events in the adenoma-carcinoma sequence. Genes Chromosomes and Cancer, 1994, 10, 190-196.	1.5	78
150	TP53 mutations are frequent in malignant NFI tumors. Genes Chromosomes and Cancer, 1994, 10, 250-255.	1.5	181
151	APC andp53 mutations in de novo colorectal adenocarcinomas. Human Mutation, 1994, 3, 342-346.	1.1	40
152	Establishment of human oral-cancer cell lines (KOSC-2 and -3) carryingp53 andc-myc abnormalities by geneticin treatment. International Journal of Cancer, 1994, 56, 301-308.	2.3	20
153	The road to the discovery of the p53 protein:The Steiner Cancer Prize Award Lecture. International Journal of Cancer, 1994, 56, 775-776.	2.3	10
154	Multifactorial analysis ofp53 alteration in human cancer: A review. International Journal of Cancer, 1994, 57, 1-9.	2.3	287
155	Aberrations of tumor-suppressor genes (p53,apc,mcc andRb) in esophageal squamous-cell carcinoma. International Journal of Cancer, 1994, 57, 21-25.	2.3	53
156	Loss of apc protein expressed by human colonic epithelial cells and the appearance of a specific low-molecular-weight form is associated with apoptosisIN vitro. International Journal of Cancer, 1994, 59, 56-64.	2.3	58
157	Correlation of cellular differentiation in human colorectal carcinoma and adenoma cell lines with metabolite profiles determined by1H magnetic resonance spectroscopy. International Journal of Cancer, 1994, 59, 248-261.	2.3	53
158	Analysis of p53 gene mutations in acute myeloid leukemia. American Journal of Hematology, 1994, 46, 304-309.	2.0	36
159	Aberrations of theAPC gene in primary breast carcinoma. Journal of Cancer Research and Clinical Oncology, 1994, 120, 727-731.	1.2	45
160	Presymptomatic diagnosis of familial adenomatous polyposis coli. Diseases of the Colon and Rectum, 1994, 37, 700-707.	0.7	17
161	p53 Mutations in COMMA-D cells. In Vitro Cellular and Developmental Biology - Animal, 1994, 30, 87-89.	0.7	25
162	p53 mutations in cervical carcinogenesis â€“ low frequency and lack of correlation with human papillomavirus status. British Journal of Cancer, 1994, 69, 732-737.	2.9	68
163	Allele loss on chromosomes 10 and 17p and epidermal growth factor receptor gene amplification in human malignant astrocytoma related to prognosis. British Journal of Cancer, 1994, 70, 684-689.	2.9	52

#	Article	IF	Citations
164	Immunohistochemical detection of p53 in differentiated, poorly differentiated and undifferentiated carcinomas of the thyroid. Histopathology, 1994, 24, 205-210.	1.6	66
165	Absence of p53 Mutations in Rat Colon Tumors Induced by 2-Amino-6-methyldipyrido[1,2-a:3â€², 2â€²-d]imidazole, 2-Amino-3-methylimidazo[4,5-f]quinoline, or 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Japanese Journal of Cancer Research, 1994, 85, 510-514.	1.7	44
166	Alteration of the p53 Tumor Suppressor Gene Occurs Independently of K-rasActivation and More Frequently in Serous Adenocarcinomas than in Other Common Epithelial Tumors of the Human Ovary. Japanese Journal of Cancer Research, 1994, 85, 1247-1256.	1.7	56
167	p53 Gene Mutations in Human Prostate Cancers in Japan: Different Mutation Spectra between Japan and Western Countries. Japanese Journal of Cancer Research, 1994, 85, 904-910.	1.7	37
168	Human wild type p53 inhibits cell proliferation and elicits dramatic morphological changes in human glioma cell lines in vitro. Journal of the Neurological Sciences, 1994, 127, 125-133.	0.3	22
169	p53 alterations in gastric carcinoma:. Cancer Genetics and Cytogenetics, 1994, 75, 45-50.	1.0	14
170	Over expression of the p53 tumor suppressor gene product in esophageal and gastric carcinomas. Pathology Research and Practice, 1994, 190, 1141-1148.	1.0	26
171	The p53 tumor suppressor gene frequently is altered in gynecologic cancers. American Journal of Obstetrics and Gynecology, 1994, 170, 246-252.	0.7	157
172	Loss of heterozygosity of tumour suppressor gene loci in human colorectal carcinoma. European Journal of Cancer, 1994, 30, 664-670.	1.3	29
173	The Role of Mitotic Recombination in Carcinogenesis. Critical Reviews in Toxicology, 1994, 24, 323-353.	1.9	71
174	The p53 tumor suppressor gene frequently is altered in gynecologic cancers. American Journal of Obstetrics and Gynecology, 1994, 170, 246-252.	0.7	130
175	Mutations in the p53 gene: An early marker of neoplastic progression in ulcerative colitis. Gastroenterology, 1994, 107, 369-378.	0.6	391
176	p53 Mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology, 1994, 106, 1589-1595.	0.6	139
177	p53: Tumor suppression through control of the cell cycle. Gastroenterology, 1994, 106, 1708-1711.	0.6	26
178	TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology, 1994, 107, 1012-1018.	0.6	162
179	Association of p53 mutations with short survival in colorectal cancer. Gastroenterology, 1994, 106, 42-48.	0.6	348
180	Molecular genetic profiles of colitis-associated neoplasms. Gastroenterology, 1994, 107, 420-428.	0.6	152
181	p53 mutations and overexpression in locally advanced breast cancers. British Journal of Cancer, 1994, 69, 1145-1150.	2.9	61

#	Article	IF	Citations
183	Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas. British Journal of Cancer, 1994, 69, 1052-1058.	2.9	65
184	Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance. British Journal of Cancer, 1994, 70, 1191-1197.	2.9	70
185	Deletion analysis of chromosome 8p in sporadic colorectal adenomas. British Journal of Cancer, 1994, 70, 18-20.	2.9	20
186	Targeting p53 as a general tumor antigen.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 11993-11997.	3.3	271
187	Evidence for a mutual regulation of p53 and c-myc expression in human colorectal cancer metastases. Annals of Oncology, 1995, 6, 981-986.	0.6	11
188	Altered p53 in microdissected, metachronous, premalignant and malignant oral lesions from the same patients. Journal of Clinical Pathology, 1995, 48, M269-M272.	2.1	8
189	Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in colorectal carcinoma: prognostic significance. Journal of Clinical Pathology, 1995, 48, M12-M16.	2.1	17
190	Tumor Suppressor p53 Mutations and Breast Cancer: A Critical Analysis. Advances in Cancer Research, 1995, 66, 71-141.	1.9	79
191	The p53 tumor suppressor gene. Advances in Genome Biology, 1995, 3, 55-141.	0.3	2
192	Frequent loss of heterozygosity on chromosome 17 at 17q11.2-q12 in Barrett's adenocarcinoma. British Journal of Cancer, 1995, 71, 995-998.	2.9	26
193	Analysis of the p53 gene in human choriocarcinoma cell lines. British Journal of Cancer, 1995, 71, 9-12.	2.9	21
194	p53 Protein Expression in Leukemias. Acta OncolÃ³gica, 1995, 34, 23-26.	0.8	3
195	Ras oncogene and p53 gene hotspot mutations in colorectal cancers. Journal of Gastroenterology and Hepatology (Australia), 1995, 10, 119-124.	1.4	2
196	Overexpression of p53 in hepatocellular carcinomas: A clinicopathological and prognostic correlation. Journal of Gastroenterology and Hepatology (Australia), 1995, 10, 250-255.	1.4	36
197	Clinicopathological and molecular biological studies of gastric adenomas with special reference to p53 abnormality. Pathology International, 1995, 45, 51-57.	0.6	31
198	Apoptosis in colorectal tumour cells: Induction by the short chain fatty acids butyrate, propionate and acetate and by the bile salt deoxycholate. International Journal of Cancer, 1995, 60, 400-406.	2.3	401
199	A low incidence of p53 mutations in pre-malignant lesions of the oral cavity from non-tobacco users. International Journal of Cancer, 1995, 60, 458-463.	2.3	47
200	p53 gene mutations in early colorectal carcinoma.de novo vs. adenoma-carcinoma sequence. International Journal of Cancer, 1995, 64, 47-51.	2.3	35

#	Article	IF	Citations
201	Microsatellite instability in japanese esophageal carcinoma. International Journal of Cancer, 1995, 64, 286-289.	2.3	30
202	Molecular analysis of genetic changes in ependymomas. Genes Chromosomes and Cancer, 1995, 13, 272-277.	1.5	68
203	Molecular pathways in the formation of gliomas. Glia, 1995, 15, 328-338.	2.5	227
204	P53 Tumor suppressor gene in chronic myelogenous leukemia: A sequential study. Annals of Hematology, 1995, 70, 129-133.	0.8	13
205	Familial breast cancer and genes involved in breast carcinogenesis. Breast Cancer Research and Treatment, 1995, 34, 171-183.	1.1	11
206	Frequency and spectrum of p53 mutations in gastric cancer ? a molecular genetic and immunohistochemical study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1995, 426, 447-55.	1.4	32
207	Gastric adenoma ? carcinoma sequence with special reference to p53 and Ki-ras gene alterations. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1995, 427, 119-24.	1.4	30
208	The sequential accumulation of genetic alterations characteristic of the colorectal adenoma-carcinoma sequence does not occur between gastric adenoma and adenocarcinoma. Journal of Pathology, 1995, 176, 249-258.	2.1	125
209	Tumor suppressor gene P53 mutations in human prostate cancer. Prostate, 1995, 27, 18-24.	1.2	49
210	p53 protein expression in colorectal adenomas: an immunohistochemical study using an antigen retrieval system. Histopathology, 1995, 27, 517-523.	1.6	10
211	p53 immunoreactivity in hepatocellular adenoma, focal nodular hyperplasia, cirrhosis and hepatocellular carcinoma. Histopathology, 1995, 26, 63-68.	1.6	34
212	Detection of p53 Gene Mutations in Aspiration Biopsy Specimens from Suspected Breast Cancers by Polymerase Chain Reaction-Single Strand Conformation Polymorphism Analysis. Japanese Journal of Cancer Research, 1995, 86, 140-145.	1.7	3
213	Mutation of the MXI1 gene in prostate cancer. Nature Genetics, 1995, 9, 249-255.	9.4	208
214	p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nature Medicine, 1995, 1, 570-577.	15.2	415
215	Microallelotyping defines the sequence and tempo of alleiic losses at tumour suppressor gene loci during colorectal cancer progression. Nature Medicine, 1995, 1, 902-909.	15.2	201
216	Colorectal carcinomas show frequent allelic loss on the long arm of chromosome 17 with evidence for a specific target region. British Journal of Cancer, 1995, 71, 1070-1073.	2.9	28
217	Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. British Journal of Cancer, 1995, 71, 1257-1262.	2.9	62
218	Familial polyposis: recent advances. Critical Reviews in Oncology/Hematology, 1995, 19, 1-31.	2.0	52

#	Article	IF	Citations
219	Neurofibromatosis 2 gene in human colorectal cancer. Cancer Genetics and Cytogenetics, 1995, 84, 24-26.	1.0	33
220	The adenomatous polyposis coli gene and human cancers. Journal of Cancer Research and Clinical Oncology, 1995, 121, 529-534.	1.2	24
221	High K-ras mutation rates in goblet-cell-type adenocarcinomas of the lungs. Journal of Cancer Research and Clinical Oncology, 1995, 121, 577-581.	1.2	34
222	Tumor Suppressor Gene Alterations in Bladder Carcinoma. Surgical Oncology Clinics of North America, 1995, 4, 231-240.	0.6	18
223	Multiple genetic lesions in laryngeal squamous cell carcinomas. Cancer, 1995, 75, 1292-1301.	2.0	32
224	Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer, 1995, 75, 1327-1338.	2.0	119
225	Expression of mutant p53 protein and CD44 variant proteins in colorectal tumorigenesis.. Gut, 1995, 36, 76-80.	6.1	61
226	Chromosome 17 Abnormalities and Inactivation of the P53 Gene in Chronic Myeloid Leukemia and Their Prognostic Significance. Leukemia and Lymphoma, 1995, 19, 213-221.	0.6	32
227	17p Anomalies in Lymphoid Malignancies: Diagnostic and Prognostic Implications. Leukemia and Lymphoma, 1995, 17, 271-279.	0.6	12
228	Screening for Colorectal Cancer. New England Journal of Medicine, 1995, 332, 861-867.	13.9	158
229	p53 Overexpression in laryngeal squamous cell carcinoma and dysplasia. Journal of Clinical Pathology, 1995, 48, M194-M197.	2.1	10
230	Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases.. Gut, 1995, 36, 455-458.	6.1	55
231	p53 expression in ulcerative colitis: a longitudinal study.. Gut, 1995, 37, 802-804.	6.1	33
232	Colorectal cancer: Future population screening for early colorectal cancer. European Journal of Cancer, 1995, 31, 1369-1372.	1.3	13
233	p53 Immunoreactive stain and early colorectal adenocarcinomas. European Journal of Cancer, 1995, 31, 2220-2222.	1.3	12
234	Presence of human papillomavirus sequences in tumour-derived human oral keratinocytes expressing mutant p53. European Journal of Cancer Part B, Oral Oncology, 1995, 31, 136-143.	0.9	50
235	Lack of p53 point mutations in chemically induced mouse hepatoblastomas: an end-stage, highly malignant hepatocellular tumor. Cancer Letters, 1995, 95, 175-180.	3.2	10
236	Passage of X-ray-induced immortal, non-transformed phenotype by DNA-mediated transfection. Cancer Letters, 1995, 97, 39-47.	3.2	2

#	Article	IF	Citations
237	bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. Human Pathology, 1995, 26, 534-540.	1.1	153
238	The clinical and genetic manifestations of hereditary nonpolyposis colorectal carcinoma. American Journal of Surgery, 1995, 169, 368-372.	0.9	15
239	Rhabdomyosarcoma of the oral cavity. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 1995, 80, 192-201.	1.6	25
240	Dr. Strange DNA, or how i learned to stop cloning and love the computer. Gastroenterology, 1995, 109, 611-614.	0.6	5
241	Flow cytometric analysis of the DNA content in colorectal adenomas with focal cancers. Gastroenterology, 1995, 109, 1098-1104.	0.6	8
242	Molecular Genetics of Colorectal Cancer. Annals of the New York Academy of Sciences, 1995, 768, 101-110.	1.8	57
243	The Spectrum of Mutations at the p53 Locus. Annals of the New York Academy of Sciences, 1995, 768, 111-128.	1.8	91
244	Genetic diagnosis of lymph-node metastasis in colorectal cancer. Lancet, The, 1995, 345, 1257-1259.	6.3	284
245	Role of Apoptosis in Biology and Pathology: Resistance to Apoptosis in Colon Carcinogenesis. Ultrastructural Pathology, 1995, 19, 221-248.	0.4	82
246	p53 mutations and overexpressions in Japanese breast cancer. European Journal of Surgical Oncology, 1995, 21, 595-600.	0.5	4
247	p53 Mutations and Prognosis in Bladder Tumors. Journal of Urology, 1995, 153, 1097-1104.	0.2	89
248	Topoisomerase-I Inhibitors in the Management of Colon Cancer. Annals of the New York Academy of Sciences, 1996, 803, 256-263.	1.8	5
249	Mutations of the p53 gene in the stool of patients with resectable colorectal cancer. Cancer, 1996, 77, 1707-1710.	2.0	78
250	Studies of the p53 gene mutation in Saudi non-Hodgkin's lymphoma. Cancer Letters, 1996, 104, 225-231.	3.2	1
251	Frequent TP53 gene alterations (mutation, allelic loss, nuclear accumulation) in primary non-small cell lung Cancer. European Journal of Cancer, 1996, 32, 335-341.	1.3	17
252	Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer. An immunohistochemical analysis. European Journal of Cancer, 1996, 32, 802-806.	1.3	55
253	p53 Protein overexpression in gallbladder carcinoma and its precursor lesions: An immunohistochemical study. Human Pathology, 1996, 27, 360-365.	1.1	108
254	Interphase Cytogenetic Analysis of Solid Tumors by Non-Isotopic DNA in situ Hybridization. Progress in Histochemistry and Cytochemistry, 1996, 31, III-133.	5.1	14

#	Article	IF	Citations
255	Lessons from Hereditary Colorectal Cancer. Cell, 1996, 87, 159-170.	13.5	4,378
256	Dominant-negative p53 mutations selected in yeast hit cancer hot spots.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 4091-4095.	3.3	158
257	Apoptosis and APC in colorectal tumorigenesis.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 7950-7954.	3.3	434
258	Tumor Suppressor p53 Gene Mutation in Squamous Cell Carcinoma of the Larynx. Diagnostic Molecular Pathology, 1996, 5, 201-205.	2.1	11
259	Genes mediating programmed cell death: an immunohistochemical study of bcl-2, c-myc and p53 expression in colorectal neoplasia. Journal of Clinical Pathology, 1996, 49, M151-M158.	2.1	16
260	Detection of circulating anti-p53 antibodies in patients with colorectal carcinoma and the antibody's relation to clinical factors. Diseases of the Colon and Rectum, 1996, 39, 1269-1274.	0.7	15
261	Overexpression of p53 protein and histologic grades of dysplasia in colorectal adenomas. Diseases of the Colon and Rectum, 1996, 39, 562-567.	0.7	7
262	The significance of P53 gene mutations and expressions in human colorectal tumors. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 1996, 8, 109-112.	0.7	0
263	Detection of point mutation of p53 gene by silver staining PCR-SSCP in paraffin-embedded malignant fibrous histiocytoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 1996, 8, 192-195.	0.7	0
264	Possible relation of p53 and mdm-2 oncoprotein expression in thyroid carcinoma: A molecular-pathological and immunohistochemical study on paraffin-embedded tissue. Endocrine Pathology, 1996, 7, 121-130.	5.2	8
265	Chromosome changes caused by alterations of p53 expression. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1996, 354, 129-138.	0.4	50
266	Immunohistochemical analysis of p53 and ras p21 expression in colorectal adenomas and early carcinomas. Surgery Today, 1996, 26, 230-235.	0.7	17
267	MDR1 expression correlates with mutantp53 expression in colorectal cancer metastases. Journal of Cancer Research and Clinical Oncology, 1996, 122, 671-675.	1.2	22
268	Alteration of the p53 gene of lung carcinomas with sarcomatous transformation (spindle cell) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.6	15
269	Molecular pathogenesis of adenoma and differentiated adenocarcinoma of the stomach. Pathology International, 1996, 46, 834-841.	0.6	33
270	Different expression of Bclâ€2 protein in gastric adenomas and carcinomas. Pathology International, 1996, 46, 274-280.	0.6	13
271	Nuclear p53 accumulation by smallâ€sized adenocarcinomas of the lung. Pathology International, 1996, 46, 486-490.	0.6	26
272	THE AETIOLOGY, INVESTIGATION AND MANAGEMENT OF SURGICAL DISORDERS OF THE THYROID GLAND. ANZ Journal of Surgery, 1996, 66, 481-490.	0.3	20

#	Article	IF	Citations
273	Apoptosis and gastrointestinal pharmacology. , 1996, 72, 149-169.		67
274	Hypoxic stress proteins: Survival of the fittest. Seminars in Radiation Oncology, 1996, 6, 46-58.	1.0	143
275	Immunohistochemical staining for the p53 protein and proliferating cell nuclear antigen in familial clustering of gastric cancer. , 1996, 62, 253-257.		3
276	p53 gene mutation is not directly related to tumoricidal effects of preoperative radiochemohyperthermia therapy for rectal cancers. , 1996, 63, 87-90.		4
277	Colorectal cancer: Molecular genetic studies and their future clinical applications. Medical and Pediatric Oncology, 1996, 27, 35-40.	1.0	6
278	Colorectal adenocarcinoma as a second malignant neoplasm following Wilms' tumor and rhabdomyosarcoma. , 1996, 27, 556-560.		17
279	Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2.0	71
280	Allelic loss of chromosome 17p, mutation of the p53 gene, and microsatellite instability in right- and left-sided colorectal cancer. , 1996, 77, 1688-1693.		44
281	Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas. Cancer, 1996, 78, 1248-1253.	2.0	69
282	Multiple early gastric carcinomas: Clinicopathologic features and histogenesis. Cancer, 1996, 78, 2078-2086.	2.0	23
283	Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: A review. , 1996, 69, 225-235.		244
284	Molecular characterization of a novel cancer cell line established from human carcinoma in pleomorphic adenoma (CaPA-4). , 1996, 67, 204-210.		7
285	Molecular analysis of the TP53 gene in Barrett's adenocarcinoma. , 1996, 7, 109-113.		13
286	Establishment of spontaneously immortalized rat type 1 astroglial cell lines: The role of p53 in astroglial carcinogenesis. , 1996, 18, 185-199.		5
287	Incidence of p53 and Ha-ras gene mutations in chemically induced rat mammary carcinomas. , 1996, 17, 78-83.		40
288	Molecular staging of head and neck squamous carcinoma. Cancer and Metastasis Reviews, 1996, 15, 3-10.	2.7	44
289	Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature, 1996, 379, 88-91.	13.7	2,223
290	Evidence for reciprocity of bcl-2 and p53 expression in human colorectal adenomas and carcinomas. British Journal of Cancer, 1996, 73, 889-895.	2.9	118

#	Article	IF	Citations
291	Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma. British Journal of Cancer, 1996, 74, 165-171.	2.9	61
292	Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. British Journal of Cancer, 1996, 74, 216-223.	2.9	79
293	Immunohistochemical Study of the Proliferating Ability and Malignant Potential of Transitional Cell Carcinoma in the Human Urinary Bladder. International Journal of Urology, 1996, 3, S32-4.	0.5	0
294	Genetic determinants of p53-induced apoptosis and growth arrest.. Genes and Development, 1996, 10, 1945-1952.	2.7	423
295	Novel Mutations Detected in the TSC2 Hene From Both Sporadic and Familial TSC Patients. Human Molecular Genetics, 1996, 5, 249-256.	1.4	81
296	Laboratory Probing of Oncogenes from Human Liquid and Solid Specimens as Markers of Exposure to Toxicants. Critical Reviews in Toxicology, 1996, 26, 483-549.	1.9	4
297	Mutations of the p53 Gene as a Prognostic Factor in Aggressive B-Cell Lymphoma. New England Journal of Medicine, 1997, 337, 529-534.	13.9	268
298	High Prevalence of p53 Gene Mutation in Esophageal Cancer. Asian Cardiovascular and Thoracic Annals, 1997, 5, 213-219.	0.2	0
299	p53 And proliferating cell nuclear antigen in endocrine tumors of pancreas and intestinal carcinoids. Pathology, 1997, 29, 147-153.	0.3	9
300	Effects of p53 mutations on apoptosis in mouse intestinal and human colonic adenomas. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 10199-10204.	3.3	66
301	Alternative genetic pathways in colorectal carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 12122-12127.	3.3	209
302	Genetic prognostic markers in colorectal cancer.. Journal of Clinical Pathology, 1997, 50, 281-288.	2.1	16
303	Allelic Imbalance and Microsatellite Instability in Resected DukeÊ¼s D Colorectal Cancer. Diagnostic Molecular Pathology, 1997, 6, 78-84.	2.1	31
304	Application of PCR-RFLP and MASA Analyses on 18S Ribosomal RNA Gene Sequence for the Identification of Three Ginseng Drugs.. Biological and Pharmaceutical Bulletin, 1997, 20, 765-769.	0.6	47
305	Cell-cell contact and specific cytokines inhibit apoptosis of colonic epithelial cells: growth factors protect against c-myc-independent apoptosis. British Journal of Cancer, 1997, 75, 960-968.	2.9	48
306	Colorectal carcinoma in Hong Kong: epidemiology and genetic mutations. British Journal of Cancer, 1997, 76, 1610-1616.	2.9	39
307	Commonly deleted region on the long arm of chromosome 7 in differentiated adenocarcinoma of the stomach. British Journal of Cancer, 1997, 76, 1567-1571.	2.9	41
308	THE GENETICS OF COLORECTAL CANCER. Surgical Clinics of North America, 1997, 77, 175-195.	0.5	31

#	Article	IF	Citations
309	THE MOLECULAR BASIS FOR CARCINOGENESIS IN METAPLASTIC COLUMNAR-LINED ESOPHAGUS. Gastroenterology Clinics of North America, 1997, 26, 583-597.	1.0	18
310	P53 and her-2 alterations in renal cell carcinoma. Urology, 1997, 50, 636-642.	0.5	27
311	Overexpression of SAP-1, a Transmembrane-Type Protein Tyrosine Phosphatase, in Human Colorectal Cancers. Biochemical and Biophysical Research Communications, 1997, 231, 705-711.	1.0	51
312	The status of p53 in the metastatic progression of colorectal cancer. European Journal of Cancer, 1997, 33, 1314-1322.	1.3	24
313	Ki-ras oncogene and p53 tumour suppressor gene mutations in colorectal carcinomas from the European Saar-Luxembourg region are less frequent than predicted by the classic adenoma-carcinoma sequence model. European Journal of Cancer, 1997, 33, 2265-2272.	1.3	8
314	Association of p53 protein expression in stage I lung adenocarcinoma with reference to cytological subtypes. Human Pathology, 1997, 28, 544-548.	1.1	16
315	Prognostic significance of serum anti-p53 antibody in patients with hepatocellular carcinoma. Journal of Hepatology, 1997, 27, 661-668.	1.8	37
316	p53 tumor suppressor gene protein expression in premalignant and malignant skin lesions of kidney transplant recipients. Journal of the American Academy of Dermatology, 1997, 36, 924-931.	0.6	21
317	Detection of p53 gene mutations in fine-needle aspiration biopsied breast cancer specimens: correlations with nuclear p53 accumulations and tumor DNA aneuploidy patterns. Cancer Letters, 1997, 115, 47-55.	3.2	10
318	Prognostic Factors in Colorectal Carcinoma. Surgical Oncology Clinics of North America, 1997, 6, 463-494.	0.6	4
319	Cancer Biology in Ulcerative Colitis and Potential Use in Endoscopic Surveillance. Gastrointestinal Endoscopy Clinics of North America, 1997, 7, 453-468.	0.6	23
320	p53 Abnormalities in B-Cell Prolymphocytic Leukemia. Blood, 1997, 89, 2015-2023.	0.6	115
321	Immunoreactive Transforming Growth Factor Î²â€1, Its Receptor, bclâ€2 Protein, and p53 Protein in Colorectal Adenomas. Digestive Endoscopy, 1997, 9, 272-277.	1.3	1
322	Demonstration ofrasandp53Gene Mutations in Carcinomas in the Forestomach and Intestine and Soft Tissue Sarcomas Induced byN-Methyl-N-nitrosourea in the Rat. Japanese Journal of Cancer Research, 1997, 88, 129-136.	1.7	31
323	P-Glycoprotein Is Positively Correlated with p53 Protein Accumulation in Human Colorectal Cancers. Japanese Journal of Cancer Research, 1997, 88, 738-742.	1.7	18
324	Expressions of Cell Cycle Regulators in Human Colorectal Cancer Cell Lines. Japanese Journal of Cancer Research, 1997, 88, 855-860.	1.7	42
325	Allelotype analysis of adenocarcinoma of the gastric cardia. British Journal of Cancer, 1997, 76, 1455-1465.	2.9	33
326	Colorectal carcinogenesis: From chromosomal evolution pathways to molecular pathogenesis. Cancer Genetics and Cytogenetics, 1997, 93, 63-73.	1.0	22

#	Article	IF	Citations
327	Analysis of p53 gene deletions in colorectal cancers using fluorescence in situ hybridization. Surgery Today, 1997, 27, 999-1004.	0.7	3
328	Chemoprevention of gastrointestinal cancer. , 1997, 16, 405-419.		13
329	Colorectal cancer screening. , 1997, 16, 263-279.		13
330	Ineffectiveness of the presence of H-ras/p53 combination of mutations in squamous cell carcinoma cells to induce a conversion of a nontumorigenic to a tumorigenic phenotype. Cell Biology and Toxicology, 1997, 13, 419-434.	2.4	12
331	Long-term outcome of patients with perianal Paget's disease. Annals of Surgical Oncology, 1997, 4, 475-480.	0.7	99
332	Topographic genotyping of colorectal carcinoma: From a molecular carcinogenesis model to clinical relevance. Annals of Surgical Oncology, 1997, 4, 269-278.	0.7	4
333	Wild-typep53 gene-induced morphological changes and growth suppression in hepatoma cells. Journal of Gastroenterology, 1997, 32, 330-337.	2.3	4
334	The role of apoptosis in intestinal disease. Journal of Gastroenterology, 1997, 32, 414-423.	2.3	13
335	Molecular genetic alteration and DNA ploidy in hereditary nonpolyposis colorectal cancer. International Journal of Clinical Oncology, 1997, 2, 224-229.	1.0	6
336	Usefulness of PCNA labeling index and p53 expression in determining prognosis in osteosarcoma. Journal of Orthopaedic Science, 1997, 2, 57-63.	0.5	2
337	WAF1 expression andp53 mutations in human colorectal cancers. Journal of Cancer Research and Clinical Oncology, 1997, 123, 118-123.	1.2	18
338	Ki-ras point mutation in codon 12 and expression ofp53 in mucin-producing tumor of the pancreas. Journal of Hepato-Biliary-Pancreatic Surgery, 1997, 4, 83-90.	2.0	1
339	Molecular genetics of colorectal cancer (part 1). Clinical Oncology, 1997, 9, 14-19.	0.6	3
340	Single-step DGGE-based mutation scanning of thep53 gene: Application to genetic diagnosis of colorectal cancer. Human Mutation, 1997, 9, 348-355.	1.1	71
341	Malignant astrocytoma-derived region of common amplification in chromosomal band 17p12 is frequently amplified in high-grade osteosarcomas. Genes Chromosomes and Cancer, 1997, 18, 279-285.	1.5	27
342	Functional characterization of p53 molecules expressed in human squamous cell carcinomas of the head and neck. , 1997, 18, 89-96.		38
343	Genetic alterations and oxidative metabolism in sporadic colorectal tumors from a Spanish community. , 1997, 18, 232-243.		81
344	Assessment of mutations in ki-ras andp53 in colon cancers from azoxymethane- and dimethylhydrazine-treated rats. , 1997, 19, 137-144.		46

#	Article	IF	Citations
345	Detection of numeric abnormalities of chromosome 17 and p53 deletions by fluorescence in situ hybridization in pleomorphic adenomas and carcinomas in pleomorphic adenoma. , 1997, 79, 2314-2319.		43
346	Conserved region mutations of thep53 gene are concentrated in distal colorectal cancers. International Journal of Cancer, 1997, 74, 97-101.	2.3	28
347	Genetic diversity at the p53 locus between primary human colorectal adenocarcinomas and their lymph-node metastases. International Journal of Cancer, 1997, 70, 674-678.	2.3	18
348	bcl-2 and bak may play a pivotal role in sodium butyrate-induced apoptosis in colonic epithelial cells; however overexpression of bcl-2 does not protect against bak-mediated apoptosis. , 1997, 72, 898-905.		86
349	Modulation of p53 expression in cultured colonic adenoma cell lines by the naturally occurring lumenal factors butyrate and deoxycholate. , 1997, 73, 702-706.		22
350	Fragment analysis of the p53 gene in ovarian tumors. Clinical Biochemistry, 1998, 31, 551-553.	0.8	1
351	Genetic instabilities in human cancers. Nature, 1998, 396, 643-649.	13.7	3,851
352	Alteration ofp53Clonality Accompanying Colorectal Cancer Progression. Japanese Journal of Cancer Research, 1998, 89, 40-46.	1.7	13
353	p53Gene Mutation and Loss of Heterozygosity of Chromosome 11 in Methylcholanthrene-induced Mouse Sarcomas. Japanese Journal of Cancer Research, 1998, 89, 269-277.	1.7	23
354	Significant Correlation of Nitric Oxide Synthase Activity andp53Gene Mutation in Stage I Lung Adenocarcinoma. Japanese Journal of Cancer Research, 1998, 89, 696-702.	1.7	46
355	Association of Loss of Heterozygosity at the p53 Locus with Chemoresistance in Osteosarcomas. Japanese Journal of Cancer Research, 1998, 89, 539-547.	1.7	51
356	Immunohistochemical detection of p53 and Bcl-2 in colorectal carcinoma: no evidence for prognostic significance. British Journal of Cancer, 1998, 77, 1842-1847.	2.9	58
357	Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis. British Journal of Cancer, 1998, 77, 2230-2238.	2.9	54
358	5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins. British Journal of Cancer, 1998, 78, 986-992.	2.9	143
359	Biology of colorectal cancer in ulcerative colitis. Journal of Gastrointestinal Surgery, 1998, 2, 307-311.	0.9	3
360	Genetic Alterations in Colorectal Cancer, Comparative Analysis of Deletion Events, and Point Mutations. Cancer Genetics and Cytogenetics, 1998, 104, 32-38.	1.0	9
361	Epidemiology and molecular genetics of colorectal cancer. Surgical Oncology, 1998, 7, 115-123.	0.8	34
362	DNA analysis at p53 locus in carcinomas arising from pleomorphic adenomas of salivary glands: Comparison of molecular study and p53 immunostaining. Pathology International, 1998, 48, 265-272.	0.6	35

#	Article	IF	Citations
363	Prognostic value of cyclin E and p53 expression in gastric carcinoma. Cancer, 1998, 82, 1238-1243.	2.0	64
364	Microsatellite instability and p53 mutations in sporadic right and left colon carcinoma. Cancer, 1998, 83, 889-895.	2.0	35
365	Correlation between 1p deletions and aneusomy in human colorectal adenomas. , 1998, 75, 45-50.		21
366	Characterization of human colon cancer antigens recognized by autologous antibodies. International Journal of Cancer, 1998, 76, 652-658.	2.3	281
367	Identification of deletions and insertions in the p53 gene using multiplex PCR and high-resolution fragment analysis: Application to breast and ovarian tumors. , 1998, 12, 250-256.		7
368	Natural history of colorectal carcinoma: Can the tumor volume doubling time be predicted by radiologic findings or immunohistochemical variables?. , 1998, 68, 215-224.		7
369	Allelic imbalance and cytogenetic deletion of 1p in colorectal adenomas: A target region identified between DIS199 and DIS234. , 1998, 21, 185-194.		24
370	Genetics of colorectal cancer. , 1998, 15, 126-130.		20
371	p53 protein overexpression and response to induction chemoradiation therapy in patients with locally advanced rectal adenocarcinoma. Annals of Surgical Oncology, 1998, 5, 203-208.	0.7	42
372	Rapid identification of Leishmania species from formalin-fixed biopsy samples by polymorphism-specific polymerase chain reaction. Gene, 1998, 210, 179-186.	1.0	39
373	Genetic alterations are frequent in APC but rare in the TGF-Î² type II receptor gene in cancer in adenomas of the colon. Cancer Letters, 1998, 125, 89-96.	3.2	9
374	p53 Exon 7 mutations as a predictor of poor prognosis in patients with colorectal cancer. Cancer Letters, 1998, 130, 153-160.	3.2	21
375	Molecular approaches to colorectal cancer: a review. Current Diagnostic Pathology, 1998, 5, 34-43.	0.4	5
376	p53 mutagenesis in klatskin tumors. Human Pathology, 1998, 29, 955-960.	1.1	10
377	Leiomyosarcoma in soft tissue: Examination of p53 status and cell proliferating factors in different locations. Human Pathology, 1998, 29, 74-81.	1.1	41
378	p53 alterations in atypical alveolar hyperplasia of the human lung. Human Pathology, 1998, 29, 801-808.	1.1	62
379	Germ-Line Mutational Analysis of the TSC2 Gene in 90 Tuberous-Sclerosis Patients. American Journal of Human Genetics, 1998, 62, 286-294.	2.6	106
380	Specific K-ras2 Mutations in Human Sporadic Colorectal Adenomas Are Associated with DNA Near-Diploid Aneuploidy and Inhibition of Proliferation. American Journal of Pathology, 1998, 153, 1201-1209.	1.9	37

#	Article	IF	Citations
381	Helicobacter pylori and Epstein-Barr virus infection and the p53 tumour suppressor pathway in gastric stump cancer compared with carcinoma in the non-operated stomach. Journal of Clinical Pathology, 1998, 51, 662-666.	1.0	42
382	Down-regulation of Vascular Endothelial Growth Factor in a Human Colon Carcinoma Cell Line Transfected with an Antisense Expression Vector Specific for c-src. Journal of Biological Chemistry, 1998, 273, 1052-1057.	1.6	169
383	p53 Gene Mutation in the Bone-Marrow of a Patient with Diffuse Mixed Cell Type Lymphoma at Diagnosis Predicting Eventual Progression to Large Cell Lymphoma. Leukemia and Lymphoma, 1998, 29, 415-421.	0.6	0
384	Prognostic Significance of p53 Protein Overexpression in Transitional Cell Carcinoma of the Renal Pelvis and Ureter. Urologia Internationalis, 1998, 60, 147-151.	0.6	8
385	Comparison of p53 and DNA content abnormalities in adenocarcinoma of the oesophagus and gastric cardia. British Journal of Cancer, 1998, 77, 277-286.	2.9	82
386	Infrequent p53 gene alterations in ulcerative colitis. Brazilian Journal of Medical and Biological Research, 1999, 32, 1083-1088.	0.7	4
387	Expression of Bcl-2, p53 Oncoprotein, and Proliferating Cell Nuclear Antigen in Renal Cell Carcinoma. European Urology, 1999, 35, 242-248.	0.9	48
388	MUC1 Expression in Intramucosal Colorectal Neoplasms. Oncology, 1999, 56, 223-231.	0.9	30
389	Unknown Primary Head and Neck Squamous Cell Carcinoma: Molecular Identification of the Site of Origin. Journal of the National Cancer Institute, 1999, 91, 599-604.	3.0	132
390	Dysregulation of Î²-Catenin is Common in Canine Sporadic Colorectal Tumors. Veterinary Pathology, 1999, 36, 228-236.	0.8	37
391	Microsatellite Instability and 8p Allelic Imbalance in Stage B2 and C Colorectal Cancers. Journal of the National Cancer Institute, 1999, 91, 1295-1303.	3.0	345
392	Adenomas and Adenoma-Like Dalms in Chronic Ulcerative Colitis: A Clinical, Pathological, and Molecular Review. American Journal of Gastroenterology, 1999, 94, 1746-1750.	0.2	131
393	p53 immunoreactivity in endometrial metaplasia with dysfunctional uterine bleeding. Histopathology, 1999, 35, 44-49.	1.6	53
394	Genetic and epigenetic contributions to colorectal cancer. Apmis, 1999, 107, 711-722.	0.9	13
395	An acidic environment leads to p53 dependent induction of apoptosis in human adenoma and carcinoma cell lines: implications for clonal selection during colorectal carcinogenesis. Oncogene, 1999, 18, 3199-3204.	2.6	171
396	Loss of p53 in F-MuLV induced-erythroleukemias accelerates the acquisition of mutational events that confers immortality and growth factor independence. Oncogene, 1999, 18, 5525-5534.	2.6	23
397	RNA synthesis block by 5,6-dichloro-1-Î²-D-ribofuranosylbenzimidazole (DRB) triggers p53-dependent apoptosis in human colon carcinoma cells. Oncogene, 1999, 18, 5765-5772.	2.6	62
398	Comparison of p53 and bcl-2 expression in initial, synchronous, and metachronous colorectal adenomas. Surgery Today, 1999, 29, 707-712.	0.7	5

#	Article	IF	Citations
399	Pathological and Karyotypic Abnormalities in Advanced Gastric Carcinomas. Cancer Genetics and Cytogenetics, 1999, 109, 45-50.	1.0	11
400	p53 mutations in tumors derived from irradiated human thyroid epithelial cells. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1999, 425, 231-238.	0.4	16
401	High-resolution deletion mapping of chromosome arm 1p in pancreatic cancer identifies a major consensus region at 1p35. , 1999, 24, 351-355.		16
402	Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: A phenotype/genotype correlation. , 1999, 25, 195-204.		238
403	Establishment and characterization of 12 human colorectal-carcinoma cell lines. , 1999, 81, 902-910.		40
404	Telomerase activation in colorectal carcinogenesis. , 1999, 189, 207-212.		23
405	BARRETT'S ESOPHAGUS. Gastroenterology Clinics of North America, 1999, 28, 917-945.	1.0	23
406	Multi-step pancreatic carcinogenesis and its clinical implications. European Journal of Surgical Oncology, 1999, 25, 562-565.	0.5	18
407	p27 Expression in Inflammatory Bowel Disease-Associated Neoplasia. American Journal of Pathology, 1999, 155, 1511-1518.	1.9	34
408	Radiation-Associated Rectal Cancer: Report of Four Cases. Digestive Surgery, 1999, 16, 238-243.	0.6	27
409	Somatic mutations of theAPC,KRAS, andTP53 genes in nonpolypoid colorectal adenomas. Genes Chromosomes and Cancer, 2000, 27, 202-208.	1.5	24
410	Specific patterns of chromosomal abnormalities are associated with RER status in sporadic colorectal cancer. Journal of Pathology, 2000, 192, 440-445.	2.1	29
411	Allelic loss is heterogeneous throughout the tumor in colorectal carcinoma. Cancer, 2000, 88, 2661-2667.	2.0	29
412	Low dose fractionated radiation enhances the radiosensitization effect of paclitaxel in colorectal tumor cells with mutant p53. Cancer, 2000, 89, 1893-1900.	2.0	4
413	Somatic mutation of thehBUB1 mitotic checkpoint gene in primary lung cancer. Genes Chromosomes and Cancer, 2000, 29, 213-218.	1.5	77
414	Analysis of K-ras codon 12 mutations and p53 overexpression in colorectal nodule-aggregating tumors. Journal of Gastroenterology and Hepatology (Australia), 2000, 15, 1151-1157.	1.4	25
415	Correlation between genetic alterations and histopathological subtypes in bronchioloâ€alveolar carcinoma and atypical adenomatous hyperplasia of the lung. Pathology International, 2000, 50, 778-785.	0.6	45
416	Correlation between morphological heterogeneity and genetic alteration within one tumor in adenocarcinomas of the lung. Pathology International, 2000, 50, 891-896.	0.6	10

#	Article	IF	Citations
417	Characterization of newly established colorectal cancer cell lines: correlation between cytogenetic abnormalities and allelic deletions associated with multistep tumorigenesis. Journal of Genetics, 2000, 79, 113-123.	0.4	3
418	Growth Characteristics of Rectal Carcinoid Tumors. Oncology, 2000, 59, 229-237.	0.9	63
419	A Novel Ras Antagonist Regulates Both Oncogenic Ras and the Tumor Suppressor p53 in Colon Cancer Cells. Molecular Medicine, 2000, 6, 693-704.	1.9	43
420	p53 from complexity to simplicity: mutant p53 stabilization, gainâ€ofâ€function, and dominantâ€negative effect. FASEB Journal, 2000, 14, 1901-1907.	0.2	154
421	Ki-ras codon 12 point and P53 mutations: a molecular examination of the main tumor, liver, portal vein, peripheral arterial blood and para-aortic lymph node in pancreatic cancer. American Journal of Gastroenterology, 2000, 95, 1939-1945.	0.2	22
422	Discordance of P53 Mutations of Synchronous Colorectal Carcinomas. Modern Pathology, 2000, 13, 131-139.	2.9	29
423	Biomaterial-Induced Sarcoma. American Journal of Pathology, 2000, 156, 1455-1467.	1.9	121
424	Growth patterns of superficially elevated neoplasia in the large intestine. Gastrointestinal Endoscopy, 2000, 51, 443-450.	0.5	19
425	Expression of facilitative glucose transporter 1 mRNA in colon cancer was not regulated by k-ras. Cancer Letters, 2000, 154, 137-142.	3.2	26
426	Diminished expression of ING1 mRNA and the correlation with p53 expression in breast cancers. Cancer Letters, 2000, 152, 15-22.	3.2	56
427	Differential growth inhibition by 5-fluorouracil in human colorectal carcinoma cell lines. European Journal of Cancer, 2000, 36, 1998-2006.	1.3	37
428	Immunohistochemical detection of mutant p53 protein in small-cell lung cancer: relationship to treatment outcome. Lung Cancer, 2000, 29, 23-31.	0.9	17
429	Dial 9-1-1 for p53: Mechanisms of p53 Activation by Cellular Stress. Neoplasia, 2000, 2, 208-225.	2.3	188
430	Squamous Cell Carcinoma of the Thyroid: An Aggressive Tumor Associated with Tall Cell Variant of Papillary Thyroid Carcinoma. Modern Pathology, 2000, 13, 742-746.	2.9	86
431	Frequent p53 mutation in brain (fetal)-type glycogen phosphorylase positive foci adjacent to human â€˜de novoâ€™ colorectal carcinomas. British Journal of Cancer, 2001, 84, 1497-1504.	2.9	7
432	Topographical analysis of p53 expression and DNA ploidy in early bronchial squamous cell carcinoma and preneoplastic lesions. Lung Cancer, 2001, 34, 351-361.	0.9	8
433	INTERNET ONCOLOGY. Hematology/Oncology Clinics of North America, 2001, 15, 583-592.	0.9	5
434	Cancer Genetics. , 2001, , 445-456.		1

#	Article	IF	Citations
435	What we could do now: molecular pathology of colorectal cancer. Journal of Clinical Pathology, 2001, 54, 206-214.	2.1	57
436	Evaluation of Metastatic Potential of Gastric Tumors by Staining for Proliferating Cell Nuclear Antigen and Chromosome 17 Numerical Aberrations. Annals of Surgical Oncology, 2001, 8, 525-532.	0.7	8
437	Mechanisms of oncogenesis in colon versus rectal cancer. Journal of Pathology, 2001, 195, 171-178.	2.1	166
438	Liver carcinogen aflatoxin B1 as an inducer of mitotic recombination in a human cell line. Molecular Carcinogenesis, 2001, 31, 125-138.	1.3	32
439	Molecular detection of cervical intraepithelial neoplasia and cervical carcinoma by microsatellite analysis of Papanicolaou smears. International Journal of Cancer, 2001, 93, 424-429.	2.3	15
440	Humoral response to p53 in human colorectal tumors: A prospective study of 1,209 patients. International Journal of Cancer, 2001, 94, 859-863.	2.3	60
441	Modeling chromosomal instability and epithelial carcinogenesis in the telomerase-deficient mouse. Seminars in Cancer Biology, 2001, 11, 227-238.	4.3	65
442	AgNOR/P53 expression compared with different grades in bladder carcinoma. International Urology and Nephrology, 2001, 33, 353-355.	0.6	3
443	Title is missing!. Molecular Biology, 2001, 35, 676-681.	0.4	0
444	A High Frequency of Allelic Loss in Oral Verrucous Lesions May Explain Malignant Risk. Laboratory Investigation, 2001, 81, 629-634.	1.7	44
445	A Prospective Study of p53 Expression and Its Correlation With Clinical Response of Radiotherapy in Nasopharyngeal Carcinoma. Laryngoscope, 2001, 111, 131-136.	1.1	13
446	Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation. Oncogene, 2001, 20, 6731-6741.	2.6	126
447	Heterogeneity ofp53Mutational Status in Intramucosal Carcinoma of the Colorectum. Japanese Journal of Cancer Research, 2001, 92, 161-166.	1.7	2
448	Lifestyle factors and Ki-ras mutations in colon cancer tumors. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2001, 483, 73-81.	0.4	71
449	Lack of Sequence Variation in Sporadic Bovine Leucosis in Regions of Tumour Suppressor Genes p53 and p16. Transboundary and Emerging Diseases, 2001, 48, 365-371.	0.6	2
450	Expression of p53 protein as a prognostic indicator of reduced survival time in diffuse-type gastric carcinoma. Pathology International, 2001, 51, 440-444.	0.6	21
451	Mutations in APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 9433-9438.	3.3	425
452	Abrogation of the radiation-induced G2 checkpoint by the staurosporine derivative UCN-01 is associated with radiosensitisation in a subset of colorectal tumour cell lines. British Journal of Cancer, 2002, 87, 352-358.	2.9	29

#	Article	IF	Citations
453	Role of tumor suppressor genes in the development of adult T cell leukemia/lymphoma (ATLL). Leukemia, 2002, 16, 1069-1085.	3.3	76
454	2 Role of immunohistochemical expression of p53 in colorectal carcinoma. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, 2002, , 139-147.	0.0	0
455	Molecular analysis of diminutive, flat, depressed colorectal lesions: Are they precursors of polypoid adenoma or early stage carcinoma?. Gastrointestinal Endoscopy, 2002, 56, 663-671.	0.5	25
456	The genetic pathogenesis of colorectal cancer. Hematology/Oncology Clinics of North America, 2002, 16, 775-810.	0.9	61
457	P53 gene mutations: Case study of a clinical marker for solid tumors. Seminars in Oncology, 2002, 29, 246-257.	0.8	71
458	Ulcerative colitis-associated neoplasia. Pathology International, 2002, 52, 195-203.	0.6	18
459	Prognostic value ofP53mutations in rectal carcinoma. International Journal of Cancer, 2002, 100, 131-135.	2.3	48
460	Detection of genetic alterations in thep53 suppressor gene and the K-ras oncogene among different grades of dysplasia in patients with colorectal adenomas. Cancer, 2002, 94, 219-227.	2.0	11
461	Telomerase activity in Stage II colorectal carcinoma. Cancer, 2002, 95, 1834-1839.	2.0	27
462	Combined DNA flow cytometry and sorting with k-ras2 mutation spectrum analysis and the prognosis of human sporadic colorectal cancer. Cytometry, 2002, 50, 216-224.	1.8	23
463	p53 As a mutagen test in breast cancer. Environmental and Molecular Mutagenesis, 2002, 39, 216-227.	0.9	30
464	Oral lichen planus has a high rate of TP53 mutations. A study of oral mucosa in Iceland. European Journal of Oral Sciences, 2002, 110, 192-198.	0.7	43
465	5-Methylcytosine as a marker for the monitoring of DNA methylation. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 781, 373-392.	1.2	34
466	Loss of heterozygosity in the clonal evolution of flat colorectal neoplasms. Journal of Pathology, 2002, 197, 298-306.	2.1	13
467	p53 expression in human rectal tissue after radiotherapy: upregulation in normal mucosa versus functional loss in rectal carcinomas. International Journal of Radiation Oncology Biology Physics, 2002, 52, 720-728.	0.4	20
468	Title is missing!. Molecular Biology, 2002, 36, 522-527.	0.4	3
469	Telomerase activity, P53 mutation and Kiâ€ras codon 12 point mutation of the peripheral blood in patients with hepato pancreato biliary diseases. Hpb, 2002, 4, 75-82.	0.1	7
470	CASE REPORT: K-ras Mutation and Loss of Heterozygosity at 17p with Î²-Catenin Accumulation in Intramucosal Carcinoma of the Ileostomy in Familial Adenomatous Polyposis: A Case Report. Digestive Diseases and Sciences, 2003, 48, 2310-2314.	1.1	12

#	Article	IF	Citations
471	Construction of a Reporter System for Fine Assessment of the p53 Activity in Cultured Cells. Molecular Biology, 2003, 37, 856-865.	0.4	2
472	Lung cancer andCYP1A1 orGSTM1 polymorphisms. Environmental Health and Preventive Medicine, 2003, 7, 230-234.	1.4	5
473	Molecular pathogenesis of thyroid cancer. Surgical Oncology, 2003, 12, 69-90.	0.8	75
474	Usefulness of endoscopic biopsy using immunostaining of p53 and Ki-67 in tumors of the ampulla of Vater. Pathology International, 2003, 53, 361-370.	0.6	10
475	Molecular defects in the pathogenesis of pituitary tumours. Frontiers in Neuroendocrinology, 2003, 24, 94-127.	2.5	73
476	Deletions of 17p are associated with transition from early to advanced colorectal cancer. Cancer Genetics and Cytogenetics, 2003, 147, 44-49.	1.0	31
477	TP53 , p14 ARF , p16 INK4a and H-ras gene molecular analysis in intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. International Journal of Cancer, 2003, 105, 196-203.	2.3	89
478	Numerical abnormalities of chromosomes 17 and 18 in sporadic colorectal cancer: Incidence and correlation with clinical and biological findings and the prognosis of the disease. Cytometry, 2003, 51B, 14-20.	1.8	10
479	The zinc finger protein OZF (ZNF146) is overexpressed in colorectal cancer. Journal of Pathology, 2003, 200, 177-182.	2.1	19
480	Chromosome aberrations in solid tumors. Nature Genetics, 2003, 34, 369-376.	9.4	702
481	Mutation analysis of BrCA1, BrCA2, and p53 versus soluble HLA class I and class II in a case of familial endometriosis. Fertility and Sterility, 2003, 79, 445-448.	0.5	11
482	Mutations in the P53 Tumor Suppressor Gene in Colorectal Cancer in Taiwan. Kaohsiung Journal of Medical Sciences, 2003, 19, 151-157.	0.8	8
483	Distribution of genetic variants in preneoplastic areas of colorectal tumours. European Journal of Surgical Oncology, 2003, 29, 491-496.	0.5	7
484	Defective p53 Post-translational Modification Required for Wild Type p53 Inactivation in Malignant Epithelial Cells with mdm2 Gene Amplification. Journal of Biological Chemistry, 2003, 278, 52890-52900.	1.6	23
485	Telomere shortening of epithelial cells characterises the adenoma-carcinoma transition of human colorectal cancer. Gut, 2003, 52, 1304-1307.	6.1	65
486	PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 1931-1936.	3.3	531
487	Comparison of Volume-rendered and Surface-rendered MR Colonography. Technology in Cancer Research and Treatment, 2003, 2, 13-17.	0.8	5
488	Lack of p53 Nuclear Immunostaining Is Not Indicative of Absence of TP53 Gene Mutations in Colorectal Adenocarcinomas. Applied Immunohistochemistry and Molecular Morphology, 2003, 11, 130-137.	0.6	18

#	Article	IF	Citations
489	Conjugated Linoleic Acid Inhibits Cell Proliferation through a p53-Dependent Mechanism: Effects on the Expression of G1-Restriction Points in Breast and Colon Cancer Cells. Journal of Nutrition, 2003, 133, 3670-3677.	1.3	83
490	Development of colonic neoplasia in p53 deficient mice with experimental colitis induced by dextran sulphate sodium. Gut, 2004, 53, 710-716.	6.1	61
491	A census of human cancer genes. Nature Reviews Cancer, 2004, 4, 177-183.	12.8	2,868
492	Identification of KrÃ¼ppel-like factor 4 as a potential tumor suppressor gene in colorectal cancer. Oncogene, 2004, 23, 395-402.	2.6	282
493	Identification of STAG1 as a key mediator of a p53-dependent apoptotic pathway. Oncogene, 2004, 23, 7621-7627.	2.6	36
494	Identification of Tcf-4 as a transcriptional target of p53 signalling. Oncogene, 2004, 23, 3376-3384.	2.6	60
495	Topographical distribution of allelic loss in individual lung adenocarcinomas with lymph node metastases. Modern Pathology, 2004, 17, 204-213.	2.9	7
496	Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis. Head and Neck, 2004, 26, 870-877.	0.9	44
497	Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Critical Reviews in Oncology/Hematology, 2004, 52, 103-116.	2.0	122
498	The Genetics of Sporadic Colon Cancer. Seminars in Colon and Rectal Surgery, 2004, 15, 128-135.	0.2	3
499	Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. British Journal of Cancer, 2004, 91, 1931-1946.	2.9	212
500	Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome. Cell, 2004, 119, 847-860.	13.5	1,140
501	Loss of Heterozygosity and Its Correlation with Expression Profiles in Subclasses of Invasive Breast Cancers. Cancer Research, 2004, 64, 64-71.	0.4	179
502	Anaplastic Thyroid Carcinoma with Humoral Hypercalcemia of Malignancy (HHM): An Autopsy Case Report. Endocrine Journal, 2004, 51, 303-310.	0.7	12
503	Juvenile polyposis coli: a facultative precancerosis with some similarities to ulcerative colitis?. Pathology Research and Practice, 2005, 201, 517-520.	1.0	5
504	Aspirin-induced nuclear translocation of NFÎºB and apoptosis in colorectal cancer is independent of p53 status and DNA mismatch repair proficiency. British Journal of Cancer, 2005, 92, 1137-1143.	2.9	39
505	Smoking may cause genetic alterations at 5q22.2â^¼q23.1 in clear-cell renal cell carcinoma. Cancer Genetics and Cytogenetics, 2005, 163, 7-11.	1.0	5
506	Correlation between p53 mutations and antibody staining in breast carcinoma. British Journal of Surgery, 2005, 80, 1410-1412.	0.1	26

#	Article	IF	Citations
507	Colorectal cancer screening in average risk individuals. Cancer Causes and Control, 2005, 16, 171-188.	0.8	39
508	Targeting STAT3 affects melanoma on multiple fronts. Cancer and Metastasis Reviews, 2005, 24, 315-327.	2.7	255
509	APC, K-ras, and p53 Gene Mutations in Colorectal Cancer Patients: Correlation to Clinicopathologic Features and Postoperative Surveillance. American Surgeon, 2005, 71, 336-343.	0.4	65
510	The molecular pathology of inflammatory bowel disease-associated neoplasia and preneoplasia. , 2003, , 711-718.		0
511	The Differential Effects of Mutant p53 Alleles on Advanced Murine Lung Cancer. Cancer Research, 2005, 65, 10280-10288.	0.4	488
512	The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut, 2005, 54, 1283-1286.	6.1	203
513	A Chromatin-associated and Transcriptionally Inactive p53-Mdm2 Complex Occurs in mdm2 SNP309 Homozygous Cells. Journal of Biological Chemistry, 2005, 280, 26776-26787.	1.6	106
514	Role of Stat3 in Regulating p53 Expression and Function. Molecular and Cellular Biology, 2005, 25, 7432-7440.	1.1	342
515	Serrated Adenomas Have a Pattern of Genetic Alterations That Distinguishes Them from Other Colorectal Polyps. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2253-2256.	1.1	23
516	Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway. Molecular Cancer Therapeutics, 2005, 4, 901-909.	1.9	52
517	Minimal uterine serous carcinoma: a clinicopathological study of 40 cases. Modern Pathology, 2005, 18, 75-82.	2.9	158
518	Mechanisms and markers of carcinogenesis and neoplastic progression. Expert Opinion on Biological Therapy, 2005, 5, 1317-1332.	1.4	5
519	Complementation of two mutant p53: Implications for loss of heterozygosity in cancer. FEBS Letters, 2005, 579, 2231-2235.	1.3	8
520	PRR5 encodes a conserved proline-rich protein predominant in kidney: analysis of genomic organization, expression, and mutation status in breast and colorectal carcinomas. Genomics, 2005, 85, 338-351.	1.3	27
521	Phenotypeâ€“genotype correlation: Challenge of intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. Head and Neck, 2006, 28, 909-915.	0.9	33
522	Germline p53 single-base changes associated with Balkan endemic nephropathy. Biochemical and Biophysical Research Communications, 2006, 342, 562-567.	1.0	19
523	Prognostic relevance of occult tumour cells in lymph nodes in colorectal cancer. European Journal of Surgical Oncology, 2006, 32, 253-258.	0.5	24
524	p53 and APC Mutations Are Detectable in the Plasma and Serum of Patients with Colorectal Cancer (CRC) or Adenomas. Annals of the New York Academy of Sciences, 2006, 906, 44-50.	1.8	41

#	Article	IF	Citations
525	Genetic instability on chromosome 17 in the epithelium of non-polypoid colorectal carcinomas compared to polypoid lesions. Cancer Science, 2006, 97, 1335-1342.	1.7	12
526	Mismatch repair, p53 and chromosomal aberrations in primary colorectal carcinomas. Acta OncolÃ³gica, 2006, 45, 61-66.	0.8	2
527	The effect of p53â€RNAi and p53 knockout on human 8â€oxoguanine DNA glycosylase (hOgg1) activity. FASEB Journal, 2006, 20, 112-114.	0.2	44
528	Molecular Biology of Colon Cancer. , 2007, , 1-31.		2
529	Polyclonal Tumors in the Mammalian Intestine: Are Interactions Among Multiple Initiated Clones Necessary for Tumor Initiation, Growth, and Progression?. Cell Cycle, 2007, 6, 44-51.	1.3	15
530	Chromosomal Instability and Supernumerary Centrosomes Represent Precursor Defects in a Mouse Model of T-Cell Lymphoma. Cancer Research, 2007, 67, 8081-8088.	0.4	15
531	Focal Adhesion Kinase and p53 Signaling in Cancer Cells. International Review of Cytology, 2007, 263, 103-153.	6.2	100
532	Overâ€expression of p53 protein as an indicator of the malignant transformation in spiradenoma. Histopathology, 1995, 26, 439-443.	1.6	26
533	Potentially malignant and malignant lesions of the lip. Role of silver staining nucleolar organizer regions, proliferating cell nuclear antigen, p53, and câ€myc in differentiation and prognosis. Journal of Oral Pathology and Medicine, 1999, 28, 252-258.	1.4	18
534	Local tumor recurrence or emergence of a new primary lesion? A molecular analysis. Journal of Oral Pathology and Medicine, 1999, 28, 381-384.	1.4	7
535	Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. Journal of Molecular Medicine, 2007, 85, 1175-1186.	1.7	218
536	p53 codon 72 polymorphism in patients affected with ulcerative colitis. Journal of Gastroenterology, 2007, 42, 456-460.	2.3	16
537	p53 regulates FAK expression in human tumor cells. Molecular Carcinogenesis, 2008, 47, 373-382.	1.3	92
538	Immunohistochemical demonstration of p53 protein in colorectal adenomas and adenocarcinomas. Reliable application of the heatâ€induced antigen retrieval method to formalinâ€fixed, paraffinâ€embedded material. Pathology International, 1994, 44, 765-770.	0.6	17
539	Folate and Vitamin B6 Intake and Risk of Colon Cancer in Relation to p53 Expression. Gastroenterology, 2008, 135, 770-780.	0.6	59
540	Epidemiology and Management Options for Colorectal Cancer in Children. Paediatric Drugs, 2008, 10, 177-192.	1.3	46
541	Transcription factor p53 can regulate proliferation, apoptosis and secretory activity of luteinizing porcine ovarian granulosa cell cultured with and without ghrelin and FSH. Reproduction, 2008, 136, 611-618.	1.1	45
542	IL-24 Induces Apoptosis of Chronic Lymphocytic Leukemia B Cells Engaged into the Cell Cycle through Dephosphorylation of STAT3 and Stabilization of p53 Expression. Journal of Immunology, 2008, 181, 6051-6060.	0.4	37

#	Article	IF	Citations
543	Comparative lesion sequencing provides insights into tumor evolution. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 4283-4288.	3.3	720
544	DNA Methylation Analysis: Providing New Insight into Human Disease. , 2009, , 131-142.		0
545	Transitions at CpG Dinucleotides, Geographic Clustering of TP53 Mutations and Food Availability Patterns in Colorectal Cancer. PLoS ONE, 2009, 4, e6824.	1.1	7
546	Review Paper: Implications of the â€œCancer Stem Cellâ€•Hypothesis on Murine Models of Colon Cancer and Colitis-associated Cancer. Veterinary Pathology, 2009, 46, 819-835.	0.8	10
547	Simultaneous Detection of Colorectal Cancer Mutations in Stool Samples with Biochip Arrays. Journal of Medical Biochemistry, 2009, 28, 285-292.	0.7	1
548	TAp73 regulates the spindle assembly checkpoint by modulating BubR1 activity. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 797-802.	3.3	113
549	Involvement of p53 gene mutations in human endometrial carcinomas. International Journal of Cancer, 1993, 53, 963-967.	2.3	38
550	The first 30 years of p53: growing ever more complex. Nature Reviews Cancer, 2009, 9, 749-758.	12.8	1,684
551	Combined Î±-methylacyl coenzyme A racemase/p53 analysis to identify dysplasia in inflammatory bowel disease. Human Pathology, 2009, 40, 166-173.	1.1	32
552	Molecular Basis of Colorectal Cancer. New England Journal of Medicine, 2009, 361, 2449-2460.	13.9	1,581
553	Atorvastatin Induces Apoptosis In Vitro and Slows Growth of Tumor Xenografts but Not Polyp Formation in Min Mice. Digestive Diseases and Sciences, 2010, 55, 3086-3094.	1.1	18
554	Circulating free tumor DNA and colorectal cancer. Gastroenterologie Clinique Et Biologique, 2010, 34, 662-681.	0.9	51
555	Growth regulation and transformation of ovarian epithelium. Cancer, 1993, 71, 545-551.	2.0	58
556	p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma. Journal of Pathology, 2010, 222, 129-137.	2.1	77
557	Focal adhesion kinase and p53 signal transduction pathways in cancer. Frontiers in Bioscience - Landmark, 2010, 15, 901.	3.0	65
558	Proliferation of aneuploid human cells is limited by a p53-dependent mechanism. Journal of Cell Biology, 2010, 188, 369-381.	2.3	401
559	Establishment and characterization of 13 human colorectal carcinoma cell lines: mutations of genes and expressions of drug-sensitivity genes and cancer stem cell markers. Carcinogenesis, 2010, 31, 1003-1009.	1.3	46
560	Lifestyle factors and p53 mutation patterns in colorectal cancer patients in the EPIC-Norfolk study. Mutagenesis, 2010, 25, 351-358.	1.0	14

#	Article	IF	Citations
561	The Genetics of Colorectal Cancer. Cancer Metastasis - Biology and Treatment, 2010, , 65-100.	0.1	0
562	A Quantitative Approach to the Loss of Heterozygosity in p 53 Allele on Detection of Human Cervical Cancer Using a BioImaging Analyzer. Asia-Oceania Journal of Obstetrics and Gynaecology, 1994, 20, 87-92.	0.0	4
563	DNA Methylation Analysis. , 2010, , 60-72.		0
564	Molecular Basis of Hereditary Colorectal Cancer. Seminars in Colon and Rectal Surgery, 2011, 22, 65-70.	0.2	3
565	Temporal Dissection of Tumorigenesis in Primary Cancers. Cancer Discovery, 2011, 1, 137-143.	7.7	240
566	DNA amplification on chromosome 13q31.1 correlated with poor prognosis in colorectal cancer. Clinical and Experimental Medicine, 2011, 11, 97-103.	1.9	5
567	Uncoupling Cancer Mutations Reveals Critical Timing of p53 Loss in Sarcomagenesis. Cancer Research, 2011, 71, 4040-4047.	0.4	76
568	Lessons from a decade of integrating cancer copy number alterations with gene expression profiles. Briefings in Bioinformatics, 2012, 13, 305-316.	3.2	46
569	From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. Journal of Clinical Investigation, 2012, 122, 464-472.	3.9	453
570	Mutant p53: one name, many proteins. Genes and Development, 2012, 26, 1268-1286.	2.7	998
571	Application of molecular techniques in the diagnosis, prognosis and management of patients with colorectal cancer: a practical approach. Human Pathology, 2012, 43, 1157-1168.	1.1	26
573	Mechanisms of GI Malignancies. , 2012, , 2129-2155.		3
575	Telomere-Driven Tetraploidization Occurs in Human Cells Undergoing Crisis and Promotes Transformation of Mouse Cells. Cancer Cell, 2012, 21, 765-776.	7.7	197
576	The p53 circuit board. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1825, 229-244.	3.3	60
577	Links between mutant p53 and genomic instability. Journal of Cellular Biochemistry, 2012, 113, 433-439.	1.2	162
578	Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians. Tumor Biology, 2013, 34, 1901-1911.	0.8	40
579	Efficient recovery of proteins from multiple source samples after trizolÂ® or trizolÂ®LS RNA extraction and long-term storage. BMC Genomics, 2013, 14, 181.	1.2	92
580	Decreased expression of the DBC2 gene and its clinicopathological significance in breast cancer: correlation with aberrant DNA methylation. Biotechnology Letters, 2013, 35, 1175-1181.	1.1	8

#	Article	IF	Citations
581	Biomarkers and Targeted Therapeutics in Colorectal Cancer. Surgical Oncology Clinics of North America, 2013, 22, 841-855.	0.6	3
582	A Transcriptional and Metabolic Signature of Primary Aneuploidy Is Present in Chromosomally Unstable Cancer Cells and Informs Clinical Prognosis. Cancer Research, 2013, 73, 6401-6412.	0.4	82
583	Microbiota impact on the epigenetic regulation of colorectal cancer. Trends in Molecular Medicine, 2013, 19, 714-725.	3.5	86
584	Targeting the p53 Pathway. Surgical Oncology Clinics of North America, 2013, 22, 747-764.	0.6	32
585	Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together!. Expert Opinion on Pharmacotherapy, 2013, 14, 2203-2220.	0.9	4
586	HZ08 reverse the aneuploidy-induced cisplatin-resistance in Gastric cancer by modulating the p53 pathway. European Journal of Pharmacology, 2013, 720, 84-97.	1.7	8
587	Genomics and epigenomics of colorectal cancer. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2013, 5, 205-219.	6.6	34
588	APC and DNA Demethylation in Cell Fate Specification and Intestinal Cancer. Advances in Experimental Medicine and Biology, 2013, 754, 167-177.	0.8	10
589	Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis. Expert Review of Clinical Pharmacology, 2013, 6, 557-564.	1.3	11
590	O6-methylguanine-DNA methyltransferase in the defense against N-nitroso compounds and colorectal cancer. Carcinogenesis, 2013, 34, 2435-2442.	1.3	84
591	Downregulation ofDLC-1Gene by Promoter Methylation during Primary Colorectal Cancer Progression. BioMed Research International, 2013, 2013, 1-7.	0.9	15
592	Molecular Pathways Involved in Colorectal Cancer: Implications for Disease Behavior and Prevention. International Journal of Molecular Sciences, 2013, 14, 16365-16385.	1.8	354
593	Ribosomal Protein S27-Like in Colorectal Cancer: A Candidate for Predicting Prognoses. PLoS ONE, 2013, 8, e67043.	1.1	32
594	The Expression of Multiple Proteins as Prognostic Factors in Colorectal Cancer: Cathepsin D, p53, COX-2, Epidermal Growth Factor Receptor, C-erbB-2, and Ki-67. Gut and Liver, 2014, 8, 13-23.	1.4	31
595	Differential control of growth, apoptotic activity and gene expression in human colon cancer cells by extracts derived from medicinal herbs,Rhazya strictaandZingiber officinaleand their combination. World Journal of Gastroenterology, 2014, 20, 15275.	1.4	25
596	MUTYH, an adenine DNA glycosylase, mediates p53 tumor suppression via PARP-dependent cell death. Oncogenesis, 2014, 3, e121-e121.	2.1	41
597	TP53 Mutation Analysis in Clinical Practice: Lessons From Chronic Lymphocytic Leukemia. Human Mutation, 2014, 35, 663-671.	1.1	24
598	Frequent lack of GNAS mutations in colorectal adenocarcinoma associated with GNASâ€mutated villous adenoma. Genes Chromosomes and Cancer, 2014, 53, 366-372.	1.5	15

#	Article	IF	Citations
599	Evolving Role of Gene Expression Signatures as Biomarkers in Early-Stage Colon Cancer. Journal of Gastrointestinal Cancer, 2014, 45, 399-404.	0.6	10
600	p53 and Hereditary Cancer. Sub-Cellular Biochemistry, 2014, 85, 1-16.	1.0	32
601	Sphingolipids in colon cancer. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2014, 1841, 773-782.	1.2	86
602	DNA Damage Response Genes and the Development of Cancer Metastasis. Radiation Research, 2014, 181, 111-130.	0.7	232
603	Progress and Opportunities in Molecular Pathological Epidemiology of Colorectal Premalignant Lesions. American Journal of Gastroenterology, 2014, 109, 1205-1214.	0.2	55
604	Prognosis and Therapeutic Implications for Emerging Colorectal Cancer Subtypes. Current Colorectal Cancer Reports, 2014, 10, 55-61.	1.0	4
605	ASPP 2 enhances Oxaliplatin (Lâ€•OHP)â€induced colorectal cancer cell apoptosis in a p53â€independent manner by inhibiting cell autophagy. Journal of Cellular and Molecular Medicine, 2015, 19, 535-543.	1.6	35
606	Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patients. Human Genome Variation, 2015, 2, 15009.	0.4	58
607	Serum anti-p53 antibody as a tumour marker for colorectal cancer screening. Ecancermedicalscience, 2015, 9, 560.	0.6	3
608	Animal Models of IBD-Associated CRC and Colorectal Cancer Tumorigenesis. Clinical Medicine Insights Therapeutics, 2015, 7, CMT.S18489.	0.4	3
609	Colitis-associated colon cancer: Is it in your genes?. World Journal of Gastroenterology, 2015, 21, 11688.	1.4	48
610	Single nucleotide polymorphism array profiling identifies distinct chromosomal aberration patterns across colorectal adenomas and carcinomas. Genes Chromosomes and Cancer, 2015, 54, 303-314.	1.5	14
611	microRNAs in the Malignant Transformation Process. Advances in Experimental Medicine and Biology, 2015, 889, 1-21.	0.8	4
612	Molecular biomarkers in colorectal carcinoma. Pharmacogenomics, 2015, 16, 1189-1222.	0.6	14
613	Colorectal Neoplasia Pathways. Gastrointestinal Endoscopy Clinics of North America, 2015, 25, 169-182.	0.6	23
614	TP53/p53 alterations and Aurora A expression in progressor and non-progressor colectomies from patients with longstanding ulcerative colitis. International Journal of Molecular Medicine, 2015, 35, 24-30.	1.8	6
615	Molecular Alterations of Colorectal Cancer with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2015, 60, 2251-2263.	1.1	38
616	Racial disparity in colorectal cancer: Gut microbiome and cancer stem cells. World Journal of Stem Cells, 2016, 8, 279.	1.3	4

#	Article	IF	Citations
617	Important molecular genetic markers of colorectal cancer. Oncotarget, 2016, 7, 53959-53983.	0.8	91
618	Modeling the Etiology of p53-mutated Cancer Cells. Journal of Biological Chemistry, 2016, 291, 10131-10147.	1.6	7
619	Nanotherapeutics promises for colorectal cancer and pancreatic ductal adenocarcinoma. , 2016, , 147-201.		3
620	LRH-1 drives colon cancer cell growth by repressing the expression of theCDKN1Agene in a p53-dependent manner. Nucleic Acids Research, 2016, 44, 582-594.	6.5	46
621	Obesity and colorectal cancer: molecular features of adipose tissue. Journal of Translational Medicine, 2016, 14, 21.	1.8	133
622	Molecular Taxonomy and Tumourigenesis of Colorectal Cancer. Clinical Oncology, 2016, 28, 73-82.	0.6	5
623	Positive regulation of Î²-cateninâ€“PROX1 signaling axis by DBC1 in colon cancer progression. Oncogene, 2016, 35, 3410-3418.	2.6	29
624	The clinical role of circulating free tumor DNA in gastrointestinal malignancy. Translational Research, 2017, 183, 137-154.	2.2	14
625	Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy. Journal of Molecular Biology, 2017, 429, 1595-1606.	2.0	219
626	Runx3 and Cell Fate Decisions in Pancreas Cancer. Advances in Experimental Medicine and Biology, 2017, 962, 333-352.	0.8	13
627	Putting p53 in Context. Cell, 2017, 170, 1062-1078.	13.5	1,355
628	Mutagenic potential of hypoxanthine in live human cells. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2017, 803-805, 9-16.	0.4	20
629	Lung tumors with distinct p53 mutations respond similarly to p53 targeted therapy but exhibit genotype-specific statin sensitivity. Genes and Development, 2017, 31, 1339-1353.	2.7	58
630	Development of a genetic sensor that eliminates p53 deficient cells. Nature Communications, 2017, 8, 1463.	5.8	15
631	Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a026054.	2.9	94
632	p53 Expression as a Diagnostic Biomarker in Ulcerative Colitis-Associated Cancer. International Journal of Molecular Sciences, 2017, 18, 1284.	1.8	37
633	Studying association of GTF2H4 , SULF1 , OAS3 , and IFNG genes polymorphism and risk of head and neck cancer in Southern Punjab, Pakistan. Meta Gene, 2018, 16, 85-89.	0.3	0
634	SNPitty. Journal of Molecular Diagnostics, 2018, 20, 166-176.	1.2	13

#	Article	IF	Citations
635	Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others. Nature Reviews Clinical Oncology, 2018, 15, 13-30.	12.5	337
636	Mechanisms of Gastrointestinal Malignancies. , 2018, , 1615-1642.		3
637	The Clinical Landscape of Circulating Tumor DNA in Gastrointestinal Malignancies. Frontiers in Oncology, 2018, 8, 263.	1.3	7
638	Fascin protein stabilization by miR-146a implicated in the process of a chronic inflammation-related colon carcinogenesis model. Inflammation Research, 2018, 67, 839-846.	1.6	8
639	Meta-Analysis Results on the Association Between TP53 Codon 72 Polymorphism With the Susceptibility to Oral Cancer. Frontiers in Physiology, 2018, 9, 1014.	1.3	5
640	A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products. PLoS ONE, 2018, 13, e0193689.	1.1	20
641	Molecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities. Seminars in Cancer Biology, 2019, 55, 37-52.	4.3	125
642	Maintenance BEZ235 Treatment Prolongs the Therapeutic Effect of the Combination of BEZ235 and Radiotherapy for Colorectal Cancer. Cancers, 2019, 11, 1204.	1.7	11
643	CRISPR-Cas9â€“mediated gene knockout in intestinal tumor organoids provides functional validation for colorectal cancer driver genes. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 15635-15644.	3.3	100
644	Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. Cell Reports, 2019, 28, 1370-1384.e5.	2.9	382
645	Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer. Clinical Cancer Research, 2019, 25, 5561-5571.	3.2	64
646	Tumor immune microenvironment and nano-immunotherapeutics in colorectal cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 21, 102034.	1.7	50
647	p53: a tumor suppressor hiding in plain sight. Journal of Molecular Cell Biology, 2019, 11, 536-538.	1.5	11
648	Human Colorectal Cancer from the Perspective of Mouse Models. Genes, 2019, 10, 788.	1.0	26
649	Transcription-independent and -dependent p53-mediated apoptosis in response to genotoxic and non-genotoxic stress. Cell Death Discovery, 2019, 5, 131.	2.0	22
650	The molecular origin and taxonomy of mucinous ovarian carcinoma. Nature Communications, 2019, 10, 3935.	5.8	110
651	Deregulation and Targeting of TP53 Pathway in Multiple Myeloma. Frontiers in Oncology, 2018, 8, 665.	1.3	47
652	Dynamic bioenergetic alterations in colorectal adenomatous polyps and adenocarcinomas. EBioMedicine, 2019, 44, 334-345.	2.7	21

#	Article	IF	Citations
653	The many faces of p53: something for everyone. Journal of Molecular Cell Biology, 2019, 11, 524-530.	1.5	108
654	Molecular Diagnostics in Colorectal Cancer. , 2019, , 143-155.		2
655	mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy. International Journal of Molecular Sciences, 2019, 20, 755.	1.8	406
656	Do Mutations Turn p53 into an Oncogene?. International Journal of Molecular Sciences, 2019, 20, 6241.	1.8	55
657	Initial and crucial genetic events in intestinalâ€type gastric intramucosal neoplasia. Journal of Pathology, 2019, 247, 494-504.	2.1	26
658	The Roles of Initiating Truncal Mutations in Human Cancers: The Order of Mutations and Tumor Cell Type Matters. Cancer Cell, 2019, 35, 10-15.	7.7	114
659	Mutant p53 in colon cancer. Journal of Molecular Cell Biology, 2019, 11, 267-276.	1.5	170
660	Pathways of Colorectal Carcinogenesis. Gastroenterology, 2020, 158, 291-302.	0.6	241
661	BTK inhibitors synergise with 5â€FU to treat drugâ€resistant TP53â€null colon cancers. Journal of Pathology, 2020, 250, 134-147.	2.1	23
662	Interplay between APC and ALDH1B1 in a newly developed mouse model of colorectal cancer. Chemico-Biological Interactions, 2020, 331, 109274.	1.7	7
663	Malignant transformation and genetic alterations are uncoupled in early colorectal cancer progression. BMC Biology, 2020, 18, 116.	1.7	16
664	Loss of wild-type p53 promotes mutant p53-driven metastasis through acquisition of survival and tumor-initiating properties. Nature Communications, 2020, 11, 2333.	5.8	33
665	p53: 800 million years of evolution and 40 years of discovery. Nature Reviews Cancer, 2020, 20, 471-480.	12.8	421
666	A p53-JAK-STAT connection involved in myeloproliferative neoplasm pathogenesis and progression to secondary acute myeloid leukemia. Blood Reviews, 2020, 42, 100712.	2.8	16
667	Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma. Cells, 2020, 9, 287.	1.8	37
668	The Interactions of DNA Repair, Telomere Homeostasis, and p53 Mutational Status in Solid Cancers: Risk, Prognosis, and Prediction. Cancers, 2021, 13, 479.	1.7	20
669	Role of MicroRNAs in the Progression and Metastasis of Colon Cancer. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2021, 21, 35-46.	0.6	8
670	Different effects of p53 protein overexpression on the survival of gastric cancer patients according to Lauren histologic classification: a retrospective study. Gastric Cancer, 2021, 24, 844-857.	2.7	14

#	Article	IF	Citations
671	Identification of Novel Mutations in Colorectal Cancer Patients Using AmpliSeq Comprehensive Cancer Panel. Journal of Personalized Medicine, 2021, 11, 535.	1.1	3
672	Cancer Genomic Profiling in Colorectal Cancer: Current Challenges in Subtyping Colorectal Cancers Based on Somatic and Germline Variants. Journal of the Anus, Rectum and Colon, 2021, 5, 213-228.	0.4	2
673	A Comprehensive Genomic Analysis Constructs miRNAâ€“mRNA Interaction Network in Hepatoblastoma. Frontiers in Cell and Developmental Biology, 2021, 9, 655703.	1.8	2
674	Spontaneous and inherited TP53 genetic alterations. Oncogene, 2021, 40, 5975-5983.	2.6	28
675	The Landmark Discovery That Paved the Way to a Mechanistic Understanding of P53 Gain of Function and Personalized Medicine. Cancer Research, 2021, 81, 4394-4396.	0.4	0
677	The Origin of Cancer. , 2004, 122, 1-22.		3
678	Molecular mechanisms of human carcinogenesis. , 2006, , 321-349.		24
679	Tumor Suppressor Genes. Cancer Treatment and Research, 2009, 149, 109-129.	0.2	3
680	p53 and Angiogenesis. , 2010, , 189-216.		1
681	Effects of Black Raspberries on Cellular and Epigenetic Biomarkers of Colon Cancer Development in Humans. , 2011, , 281-303.		2
682	Karyotypic Characteristics of Colorectal Tumors. , 1997, , 151-168.		5
684	TP53 Aberrations in Chronic Lymphocytic Leukemia. Advances in Experimental Medicine and Biology, 2013, 792, 109-131.	0.8	15
685	The p53 tumor-suppressor gene in human breast cancer. Cancer Treatment and Research, 1994, 71, 63-77.	0.2	15
686	Genetic Aspects of Cancer. , 1993, 21, 321-376.		13
687	Normal and malignant growth control by p53. Cancer Treatment and Research, 1993, 63, 327-344.	0.2	9
688	Folate Status: Modulation of Colorectal Carcinogenesis. Developments in Cardiovascular Medicine, 1997, , 167-176.	0.1	1
689	Advances in rectal cancer treatment. Cancer Treatment and Research, 1997, 90, 29-49.	0.2	1
690	Radiation-induced endocrine tumors. Cancer Treatment and Research, 1997, 89, 141-161.	0.2	10

#	Article	IF	Citations
691	p53 in Human Cancer. , 1995, , 77-110.		4
692	The Role of Genomic Instability in the Development of Human Cancer. , 2002, , 115-142.		9
693	DNA Methylation and cancer. , 1993, 64, 487-509.		25
694	P53 Gene Alterations in Human Tumors: Perspectives for Cancer Control. Recent Results in Cancer Research, 1997, 143, 369-389.	1.8	48
695	Astrocytic Gliomas: Characterization on a Molecular Genetic Basis. Recent Results in Cancer Research, 1994, 135, 33-42.	1.8	24
696	Wild-Type versus Mutant p53. Molecular Biology Intelligence Unit, 1995, , 19-54.	0.2	2
697	Polymerase Chain Reaction and Its Use in Diagnostics. , 1993, , 389-410.		4
698	Colonic Carcinoma: A Common Tumor with Multiple Genomic Abnormalities. , 1994, , 47-91.		3
699	p53 Autoantibodies and Cancer: Specificity, Diagnosis and Monitoring. , 2000, , 181-191.		2
700	Molecular cloning of a human transmembrane-type protein tyrosine phosphatase and its expression in gastrointestinal cancers.. Journal of Biological Chemistry, 1994, 269, 2075-2081.	1.6	62
701	Role of tumor suppressor genes in the development of adult T cell leukemia/lymphoma (ATLL). , 0, .		1
702	p53 Overexpression and Mutation in Endometrial Carcinoma: Inverted Relation with Estrogen and Progesterone Receptor Status. Cancer Detection and Prevention, 1999, 23, 147-154.	2.1	32
703	Hypermutability in Carcinogenesis. Genetics, 1998, 148, 1619-1626.	1.2	49
704	Ki-67, p53, and Bcl-2 Expression of Serrated Adenomas of the Colon. American Journal of Surgical Pathology, 1997, 21, 417-423.	2.1	66
705	Barrett's Esophagus. Annals of Surgery, 1997, 225, 17-30.	2.1	74
706	Development of Flat Adenoma and Superficial Rectal Cancer After Pelvic Radiation. Journal of Clinical Gastroenterology, 1998, 26, 171-174.	1.1	6
708	The amino-terminal functions of the simian virus 40 large T antigen are required to overcome wild-type p53-mediated growth arrest of cells. Journal of Virology, 1994, 68, 1334-1341.	1.5	76
709	LncRNAs: Master Regulators in Disease and Cancer. Proceedings of the Singapore National Academy of Science, 2020, 14, 79-89.	0.1	3

#	Article	IF	Citations
710	Auto-antibodies to p53 and the Subsequent Development of Colorectal Cancer in a U.S. Prospective Cohort Consortium. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2729-2734.	1.1	5
711	A Combined Proteomics and Mendelian Randomization Approach to Investigate the Effects of Aspirin-Targeted Proteins on Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 564-575.	1.1	10
712	High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.. Journal of Clinical Investigation, 1993, 91, 179-184.	3.9	580
713	A benign cultured colon adenoma bears three genetically altered colon cancer oncogenes, but progresses to tumorigenicity and transforming growth factor-beta independence without inactivating the p53 tumor suppressor gene.. Journal of Clinical Investigation, 1994, 93, 1005-1013.	3.9	57
714	Capicua suppresses colorectal cancer progression via repression of ETV4 expression. Cancer Cell International, 2020, 20, 42.	1.8	16
715	Genetic Aberrations in Human Brain Tumors. Neurosurgery, 1994, 34, 708-722.	0.6	67
716	Selective Expression of Mutated p53 in Human cells Immortalized with either 4-nitroquinoline 1-oxide or 60Co Gamma Rays.. Cell Structure and Function, 1996, 21, 111-116.	0.5	1
718	Reduction of Orc6 Expression Sensitizes Human Colon Cancer Cells to 5-Fluorouracil and Cisplatin. PLoS ONE, 2008, 3, e4054.	1.1	32
719	The Temporal Order of Genetic and Pathway Alterations in Tumorigenesis. PLoS ONE, 2011, 6, e27136.	1.1	99
720	Endogenous Human MDM2-C Is Highly Expressed in Human Cancers and Functions as a p53-Independent Growth Activator. PLoS ONE, 2013, 8, e77643.	1.1	23
721	TP53 Pro72 Allele Is Enriched in Oral Tongue Cancer and Frequently Mutated in Esophageal Cancer in India. PLoS ONE, 2014, 9, e114002.	1.1	11
722	Amplicon Sequencing of Colorectal Cancer: Variant Calling in Frozen and Formalin-Fixed Samples. PLoS ONE, 2015, 10, e0127146.	1.1	34
723	Expression of p53, bcl-2, and ki-67 Proteins in the Inï¬,ammatory Regenerative and Dysplastic Epithelial Lesions of Flat Colonic Mucosa. Bosnian Journal of Basic Medical Sciences, 2018, 6, 39-45.	0.6	5
724	A seven-gene signature predicts overall survival of patients with colorectal cancer. Oncotarget, 2017, 8, 95054-95065.	0.8	54
725	Whole-exome sequencing identified mutational profiles of high-grade colon adenomas. Oncotarget, 2017, 8, 6579-6588.	0.8	27
726	Thymine DNA Glycosylase (TDG) is involved in the pathogenesis of intestinal tumors with reduced APC expression. Oncotarget, 2017, 8, 89988-89997.	0.8	18
727	Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities. Oncotarget, 2016, 7, 5401-5415.	0.8	26
728	Using p53-immunostained large specimens to determine the distal intramural spread margin of rectal cancer. World Journal of Gastroenterology, 2006, 12, 1626.	1.4	5

#	Article	IF	Citations
729	Targeting mTOR network in colorectal cancer therapy. World Journal of Gastroenterology, 2014, 20, 4178.	1.4	85
730	Infrequentp53gene mutation and expression of the cardia adenocarcinomas from a high-incidence area of Southwest China. World Journal of Gastroenterology, 2000, 6, 750.	1.4	6
731	A Clinicopathological Study on Rectal Carcinoid with Special Reference to Immunohistochemical Factors of Malignant Potential.. Nihon Daicho Komonbyo Gakkai Zasshi, 1997, 50, 163-176.	0.1	5
732	p53 mutation in patients with ulcerative colitis in rectal biopsy. Korean Journal of Internal Medicine, 1998, 13, 110-116.	0.7	7
733	Impact of KRAS Mutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy. Cancer Research and Treatment, 2013, 45, 55-62.	1.3	14
734	Can Serum be Used for Analyzing the <i>KRAS</i> Mutation Status in Patients with Advanced Colorectal Cancer?. Cancer Research and Treatment, 2015, 47, 796-803.	1.3	6
735	Relationship between p53, p21 and Apoptosis in Colorectal Cancer.. Japanese Journal of Gastroenterological Surgery, 2000, 33, 1751-1757.	0.0	0
736	CLINICOPATHOLOGIC SIGNIFICANCE OF APOPTOSIS REIATED GENE PRODUCTS, bcl-2 AND p53, AND PCNA LABELING INDEX IN COLORECTAL CANCER. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical) Tj ETQq1 1 0.784314 rgBT /Ove		
737	Adrenocortical Tumors and Oncogenes. , 2001, , 219-230.		2
738	A Case of Advanced Synchronous Triple Cancer of the Colon. Japanese Journal of Gastroenterological Surgery, 2002, 35, 97-101.	0.0	1
739	Value of P53 Protein Expression and its Relationship with Short-Term Prognosis in Colorectal Cancer. Annals of Saudi Medicine, 2002, 22, 377-380.	0.5	2
740	The molecular pathology of inflammatory bowel disease-associated neoplasia and preneoplasia. , 2003, , 711-718.		0
741	Recent Advances in Molecular Classification and Prognosis of Colorectal Cancer. , 2004, , 429-451.		0
742	Genetische Grundlagen der Kanzerogenese. , 2004, , 75-145.		1
743	Mechanisms of Gastrointestinal Malignancies. , 2006, , 477-498.		0
744	Manipulating the p53 Gene in the Mouse: Organismal Functions of a Prototype Tumor Suppressor. , 2007, , 183-207.		0
745	Focal Adhesion Kinase with the Interacting Proteins and Signaling in Cancer. , 2010, , 275-305.		0
746	Colonic Polyps and Polyposis Syndromes. , 2010, , 2155-2189.e7.		8

#	Article	IF	Citations
747	Barrettâ€™s Oesophagus. , 2011, , 315-340.		0
748	FluSiM Simulation for Malaysia: Toward sImproved Pandemic Surveillance. International Journal of Chemical Engineering and Applications (IJCEA), 2011, , 53-59.	0.3	1
750	Medizinische Grundlagen. , 2012, , 19-30.		2
751	Molecular Pathology of Colon and Small Bowel Cancers: Sporadic Type. Molecular Pathology Library, 2013, , 131-140.	0.1	0
752	A Study of Immunohistochemical Reactivity of ras and p53 in Flat Type Neoplastic Lesion of Colorectum.. Nihon Daicho Komonbyo Gakkai Zasshi, 1992, 45, 196-201.	0.1	0
753	Biological Phenotypes of Tumor-Derived Human p53 Mutants. , 1993, , 231-236.		0
754	Screening of Point Mutations on p53 Gene in Primary Lung Cancer using Single-Strand Conformation Polymorphism Analysis of Polymerase Chain Reaction.. Japanese Journal of Lung Cancer, 1993, 33, 19-28.	0.0	0
755	Therapeutic Implications of Molecular Genetics. Advances in Experimental Medicine and Biology, 1993, 339, 297-304.	0.8	0
756	Familial Factors in Cancer of the Genitourinary Tract. Recent Results in Cancer Research, 1994, 136, 306-321.	1.8	0
757	Immunohistochemical Study of p53 Protein in Colon, Gastric and Lung Cancer andComparison with the Study of Genetic Alteration by the Method of Reverse Transcription Polymerase Chain Reaction Single Strand Conformation Polymorphisms.. Japanese Journal of Gastroenterological Surgery, 1994, 27, 71-77.	0.0	0
759	Immunohistochemical Expression of p53 in Relation to Proliferative Potential and Prognosis in Lung Cancer.. Japanese Journal of Lung Cancer, 1994, 34, 153-159.	0.0	0
760	Genetic Alterations in Colon Cancer. , 1995, , 139-189.		0
761	Towards Understanding the Molecular Basis of Thyroid Cancer. Annals of Saudi Medicine, 1995, 15, 252-275.	0.5	0
762	A Model for the Molecular Pathogenesis of Astrocytic Gliomas. , 1996, , 173-186.		0
763	Studies of Retinoblastoma and p53 Gene Mutations in Human Astrocytomas. , 1996, , 247-253.		0
764	A Case of Gastric Cancer (IIc type) with p53 Positive Immunohistochemical Staining Performed Three Years before the Definitive Diagnosis. Progress of Digestive Endoscopy(1972), 1996, 48, 104-106.	0.0	0
765	åšç™ºå§è…¸è…«ç˜ã•ã‚‰ã¿ãŸp53è›‹ç™½ç™ºç¾ã®è‡¨åºŠçš„æ„ç¾©. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese Col		
766	Clinicopathological Significance of p 53 and mdm 2 and PCNA LI in Colorectal Cancers.. Nihon Daicho Komonbyo Gakkai Zasshi, 1996, 49, 112-125.	0.1	1

#	Article	IF	Citations
767	Advances in screening for colorectal cancer. Cancer Treatment and Research, 1996, 86, 51-76.	0.2	1
768	Chronological study of genetic alterations during progression of DMBA-induced squamous cell carcinomas of the cheek pouch in golden hamsters.. Nihon Koku Geka Gakkai Zasshi, 1996, 42, 347-362.	0.0	0
769	Immunohistochemical Factors Influencing Growth Speed and Development of Colorectal Cancer.. Nihon Daicho Komonbyo Gakkai Zasshi, 1996, 49, 455-462.	0.1	0
770	Immunohistochemical Study of the Proliferating Ability and Malignant Potential of Transitional Cell Carcinoma in the Human Urinary Bladder. International Journal of Urology, 1996, 3, s32-s34.	0.5	1
771	Potential of Molecular Biology in Preoperative Evaluation. , 1997, , 101-114.		0
772	Neoplastic Progression in Barrettâ€™s Esophagus. , 1997, , 195-214.		0
773	Prognostic Factors in the Patients with Carcinoma of the Middle and Lower Bile Duct. Analysis of Nuclear DNA Content, MIB-1 Score and Expression of the p53 Protein.. Japanese Journal of Gastroenterological Surgery, 1997, 30, 2265-2273.	0.0	0
774	Expression of p53 Protein in Colorectal Tumorigenesis.. Nihon Daicho Komonbyo Gakkai Zasshi, 1997, 50, 227-233.	0.1	1
776	Immunohistological Characteristics of Colorectal Polyps with Advanced Colorectal Carcinoma.. Japanese Journal of Gastroenterological Surgery, 1997, 30, 2274-2281.	0.0	0
777	The molecular genetics of colonic cancer. Cancer Treatment and Research, 1998, 98, 351-382.	0.2	1
778	p53 Overexpression and its Relationship to Clinicopathological Factors and Prognosis in Colorectal Cancer.. Nihon Daicho Komonbyo Gakkai Zasshi, 1998, 51, 201-208.	0.1	2
779	Screening for Pancreatic Cancer Using Techniques to Detect Altered Gene Products. , 1998, , 113-136.		0
780	Immunohistochemical expression of bcl-2 and p53 oncoproteins in colorectal adenomas and adenocarcinomas. Annals of Cancer Research and Therapy, 1998, 7, 29-33.	0.1	0
781	Expression von p53 und Onkogenen beim Colitis ulcerosa assoziierten kolorektalen Karzinom. Langenbecks Archiv Fuˆr Chirurgie Supplement, 1999, , 391-395.	0.0	0
782	Immunohistochemical Analysis of Metastasis-Associated Gene(MTA1) Expression in Colorectal Tumors.. Nihon Daicho Komonbyo Gakkai Zasshi, 1999, 52, 310-320.	0.1	0
783	Colorectal Cancer Stem Cells. , 2015, , 227-245.		0
786	Mutation of the endogenous p53 gene in cells transformed by HPV-16 E7 and EJ c-ras confers a growth advantage involving an autocrine mechanism. EMBO Journal, 1994, 13, 1084-92.	3.5	6
787	The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation. EMBO Journal, 1993, 12, 1029-37.	3.5	36

#	Article	IF	Citations
788	The molecular genetics of colorectal carcinoma--knowledge for knowledge's sake?. Western Journal of Medicine, 1991, 154, 733-4.	0.3	0
790	Molecular analysis of oral lichen planus. A premalignant lesion?. American Journal of Pathology, 1997, 151, 323-7.	1.9	93
791	p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. American Journal of Pathology, 1997, 150, 177-85.	1.9	276
792	Early alteration of cell-cycle-regulated gene expression in colorectal neoplasia. American Journal of Pathology, 1996, 149, 381-7.	1.9	76
793	p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. American Journal of Pathology, 1995, 147, 790-8.	1.9	116
794	The relationship of quantitative nuclear morphology to molecular genetic alterations in the adenoma-carcinoma sequence of the large bowel. American Journal of Pathology, 1992, 141, 797-804.	1.9	44
795	Concurrent p53 expression in bronchial dysplasias and squamous cell lung carcinomas. American Journal of Pathology, 1993, 142, 725-32.	1.9	71
796	p53 expression in colorectal adenomas. American Journal of Pathology, 1993, 142, 87-93.	1.9	61
797	K-ras mutations and p53 alterations in neoplastic and nonneoplastic lesions associated with longstanding ulcerative colitis. American Journal of Pathology, 1994, 144, 767-75.	1.9	88
798	Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. American Journal of Pathology, 1994, 144, 889-95.	1.9	102
799	Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas. American Journal of Pathology, 1994, 145, 345-55.	1.9	63
800	Hereditary nonpolyposis colon cancer: analysis of linkage to 2p15-16 places the COCA1 locus telomeric to D2S123 and reveals genetic heterogeneity in seven Canadian families. American Journal of Human Genetics, 1994, 54, 1067-77.	2.6	16
802	Colorectal Cancer Screening: A Comprehensive Review to Recent Non-Invasive Methods. International Journal of Hematology-Oncology and Stem Cell Research, 2017, 11, 250-261.	0.3	16
804	Non-Random Selection of Cancer-Causing Mutations in Tissue-Specific Stem Cells Cause Cancer. Journal of Clinical Oncology and Research, 2020, 8, .	0.5	1
805	Neutrophils in Rectal Cancerâ€"A Review: Stage III Rectal Cancer Patients and 5-Fluorouracil Therapy. Introducing New Inclusion Criteria and Scoring System (Presenting the â€œSarandria Scoreâ€). Journal of Cancer Therapy, 2021, 12, 674-688.	0.1	2
806	Chirurgische Onkologie. , 2022, , 369-381.		0
807	Using VBIM Technique to Discover ARMC4/ODAD2 as a Novel Negative Regulator of NF-ÎºB and a New Tumor Suppressor in Colorectal Cancer. International Journal of Molecular Sciences, 2022, 23, 2732.	1.8	7
809	Manipulating the p53 Gene in the Mouse: Organismal Functions of a Prototype Tumor Suppressor. , 2007, , 183-207.		0

#	Article	IF	Citations
810	P53 Tumor suppressor gene in chronic myelogenous leukemia: a sequential study. Annals of Hematology, 1995, 70, 129-133.	0.8	3
811	p53è°ƒæŽ§è‚¿ç˜¤æ»£è°¢çš„ç”Ÿç©¶è¿›å±•. Scientia Sinica Vitae, 2022, , .	0.1	0
812	High sensitivity and rapid detection of KRAS and BRAF gene mutations in colorectal cancer using YbTixOy electrolyte-insulator-semiconductor biosensors. Materials Today Chemistry, 2022, 25, 100979.	1.7	2
813	A Literature Review in Immuno-Oncology: Pathophysiological and Clinical Features of Colorectal Cancer and the Role of the Doctor-Patient Interaction. Journal of Cancer Therapy, 2022, 13, 654-684.	0.1	1